Option Implied Volatility Rankings
This leaderboard shows a list of companies with the highest/lowest Option Implied Volatility.
Important Note: This ranking is updated several times a day, but there is often a lag between when the underlying data is updated and when the ranking reflects the new values. Please ensure you compare the actual values on this page with the values on the stock pages to ensure they are current before drawing any conclusions from the rankings.
- OptionImpliedVolatility
- The at the money implied vol, 30 day interpolated term.
Last update: 2025-09-06T00:07:01.409266Z
| Rank | Security | Industry | Market Cap (MM) | Option Implied Volatility | |
|---|---|---|---|---|---|
| 1 |
|
PYXS / Pyxis Oncology, Inc. | Pharmaceutical Preparations | 118.76 | 6.84 |
| 2 |
|
ABVC / ABVC BioPharma, Inc. | Pharmaceutical Preparations | 50.20 | 6.05 |
| 3 |
|
KIDZ / Classover Holdings, Inc. | 8.02 | 6.01 | |
| 4 |
|
VERU / Veru Inc. | Pharmaceutical Preparations | 49.66 | 6.01 |
| 5 |
|
WHWK / Whitehawk Therapeutics, Inc. | Pharmaceutical Preparations | 85.30 | 5.72 |
| 6 |
|
ENTX / Entera Bio Ltd.
Entera Bio Ltd. is a biotechnology company based in Israel, primarily focused on the development of orally delivered large molecule therapeutics for use in areas traditionally addressed by injections. A prominent player in the biopharmaceutical sector, the company utilizes its proprietary drug delivery platform to enhance the oral bioavailability of drugs. Noteworthy projects include the advancement of EB613, an oral human parathyroid hormone targeting osteoporosis, which has demonstrated promising Phase 2 results in improving bone mineral density. Entera's innovative approach aims to transform the administration of biologics, thereby potentially improving compliance and outcomes in conditions requiring chronic treatment. The company's strategic initiatives and scientific progress underscore its commitment to revolutionizing the field of therapeutics with oral delivery technologies. |
Biological Products, Except Diagnostic Substances (Biotech) | 80.00 | 5.50 |
| 7 |
|
TLPH / Talphera, Inc.
Talphera, Inc. is an American technology firm specializing in artificial intelligence and machine learning. Based in Silicon Valley, it primarily develops advanced AI algorithms and data analytics solutions aimed at enhancing predictive capabilities in various tech-driven sectors. Key projects include the development of a proprietary AI platform that assists in real-time decision-making processes for financial services and an innovative machine-learning application that enhances automation in manufacturing environments. These initiatives underscore Talphera's commitment to pushing the boundaries of AI technology to drive efficiency and innovation. The company has successfully partnered with major industry players, positioning itself as a crucial contributor to technological advancements in AI applications. |
Pharmaceutical Preparations | 10.93 | 5.26 |
| 8 |
|
ATYR / aTyr Pharma, Inc.
aTyr Pharma, Inc. is an American biotechnology company based in San Diego, California, specializing in the discovery and development of innovative medicines based on novel biological pathways. Its primary focus is on therapeutics that harness the potential of tRNA synthetases. One of the key projects is centered around ATYR1923 (efzofitimod), a fusion protein in clinical development for the treatment of various severe inflammatory lung diseases, including pulmonary sarcoidosis and interstitial lung disease. aTyr Pharma leverages its proprietary knowledge of tRNA synthetase biology to target underserved patient populations with grievous diseases, positioning itself strategically within the biotech industry to address significant unmet medical needs. |
Biological Products, Except Diagnostic Substances (Biotech) | 521.01 | 5.16 |
| 9 |
|
TXMD / TherapeuticsMD, Inc.
TherapeuticsMD, Inc., based in the United States, operates primarily within the healthcare sector, focusing on women's health. The company is dedicated to developing and commercializing products that target specific conditions experienced by women, primarily revolving around menopause-related hormone therapy. Key products from TherapeuticsMD include ANNOVERA®, BIJUVA®, and IMVEXXY®, which are innovative treatments designed to address the hormonal needs and challenges of menopausal women. These products exemplify the company's commitment to advancing the quality of healthcare for women through targeted, scientifically backed therapies. Through its specialized focus, TherapeuticsMD continues to strive for impactful solutions in the niche area of women's health. |
Pharmaceutical Preparations | 12.39 | 4.60 |
| 10 |
|
TRDA / Entrada Therapeutics, Inc. | Pharmaceutical Preparations | 187.70 | 4.49 |
| 11 |
|
PEPG / PepGen Inc. | Pharmaceutical Preparations | 45.59 | 4.45 |
| 12 |
|
STTK / Shattuck Labs, Inc. | Pharmaceutical Preparations | 74.73 | 4.11 |
| 13 |
|
SERA / Sera Prognostics, Inc. | Medical Laboratories | 127.01 | 3.97 |
| 14 |
|
ANVS / Annovis Bio, Inc.
Annovis Bio is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer's disease (AD), Parkinson's disease (PD) and Alzheimer's in Down Syndrome (AD-DS). |
Pharmaceutical Preparations | 44.82 | 3.96 |
| 15 |
|
CMBM / Cambium Networks Corporation | Radio and Television Broadcasting and Communications Equipment | 3.85 | |
| 16 |
|
DFLI / Dragonfly Energy Holdings Corp. | Miscellaneous Electrical Machinery, Equipment, and Supplies | 10.40 | 3.73 |
| 17 |
|
CODX / Co-Diagnostics, Inc.
Co-Diagnostics, Inc., based in the United States, operates primarily within the biotechnology sector, focusing on the design, development, and commercialization of cost-effective molecular diagnostics solutions. Leveraging patented CoPrimer™ technology, the company creates diagnostic tests for public health, infectious diseases, and genetic disorders, emphasizing tests for tuberculosis, Zika, COVID-19, and malaria. Co-Diagnostics, Inc. combines rigorous research and development practices to create diagnostic tools that are accurate, scalable, and accessible, aiming to serve global markets, including underdeveloped or remote regions. This strategic focus not only addresses high-demand medical needs but also positions the company to navigate complex regulatory landscapes and rapidly evolving healthcare challenges efficiently. |
Surgical and Medical Instruments and Apparatus | 11.21 | 3.63 |
| 18 |
|
CATX / Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., based in the United States, operates within the biotechnology sector with a primary focus on the development of targeted radiotherapeutics for cancer treatment. At the core of its portfolio is a series of projects aimed at advancing the use of radiolabeled small molecules and antibodies that selectively target and destroy cancer cells while minimizing exposure to healthy tissues. The company emphasizes innovation in the radioisotope drug conjugate space, specifically developing therapies that employ isotopes like Actinium-225 and Lutetium-177. These efforts are driven by the aim to improve treatment outcomes and extend survival rates for patients battling various malignancies, marking Perspective Therapeutics as a key player in the oncological radiotherapy industry. |
Pharmaceutical Preparations | 257.32 | 3.45 |
| 19 |
|
ARMP / Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc., based in the United States, operates primarily in the biotechnology industry, focusing on the development of bacteriophage-based therapies. The company's pioneering work centers on capitalizing on phage therapy to combat bacterial infections, particularly those resistant to traditional antibiotics. One of their key projects includes a proprietary platform designed to generate and optimize such bacteriophages for therapeutic use. Armata Pharmaceuticals is committed to addressing critical gaps in treating bacterial infections across various patient populations and has been actively collaborating with global healthcare entities to expand and enhance the utility of phage therapy, reflecting a significant contribution to innovative antibacterial treatments. |
Biological Products, Except Diagnostic Substances (Biotech) | 103.17 | 3.37 |
| 20 |
|
ALXO / ALX Oncology Holdings Inc. | Pharmaceutical Preparations | 65.55 | 3.33 |
| 21 |
|
HOLO / MicroCloud Hologram Inc. | Computer Programming, Data Processing, And Other Computer Related Services | 64.68 | 3.27 |
| 22 |
|
KZR / Kezar Life Sciences, Inc.
Kezar Life Sciences, Inc., based in the United States, operates within the biotechnology sector focusing on the discovery and development of novel treatments for autoimmune diseases and cancer. Since its inception, the company has been committed to advancing healthcare through breakthrough scientific research. A key project involves its innovative drug candidate, KZR-616, which is designed as a selective immunoproteasome inhibitor with potential applications across multiple autoimmune diseases. In addition, Kezar Life Sciences explores the development of small molecules targeting protein secretion pathways for various malignancies. Their strategic approach combines cutting-edge science with targeted therapies to address significant unmet medical needs in both disease areas. |
Pharmaceutical Preparations | 29.97 | 3.26 |
| 23 |
|
APT / Alpha Pro Tech, Ltd.
Alpha Pro Tech, Ltd. is a company based in Canada, prominently active in the development, manufacturing, and marketing of protective apparel and infection control products. The company operates through two main divisions: Building Supply and Disposable Protective Apparel. In the Building Supply sector, its products, including synthetic roof underlayment and housewrap, cater to the construction industry, enhancing the safety and durability of architectural structures. Meanwhile, the Disposable Protective Apparel division focuses on producing face masks, shields, and medical coverings, which are crucial in controlling infections in healthcare settings. Alpha Pro Bed Tech significantly contributes to public health safety, especially highlighted during health crises such as the COVID-19 pandemic, where its products saw increased demand. Through these initiatives, Alpha Pro Tech aims to expand its market reach and fortify its contribution to safety in both healthcare and construction industries. |
Orthopedic, Prosthetic, and Surgical Appliances and Supplies | 50.88 | 3.24 |
| 24 |
|
TKNO / Alpha Teknova, Inc. | In Vitro and In Vivo Diagnostic Substances | 233.04 | 3.20 |
| 25 |
|
TLSA / Tiziana Life Sciences Ltd | Pharmaceutical Preparations | 3.17 | |
| 26 |
|
CAPT / Captivision Inc. | 3.16 | ||
| 27 |
|
CSBR / Champions Oncology, Inc.
Champions Oncology, Inc., based in the United States, operates primarily in the biotechnology industry with a significant focus on developing advanced technology solutions and services in cancer research. Founded in 2007, the company specializes in leveraging its technology platforms to personalize oncology drugs and treatments through predictive models derived from implantable human tumors in mice. These tumorgraft models are pivotal in their translational oncology research, assisting pharmaceutical and biotechnology companies in evaluating preclinical and clinical trials of their cancer therapies, thus accelerating their development. Champions Oncology is actively expanding its research reach and continues to innovate in personalized cancer treatment, contributing advancements to the oncology field. |
Biological Products, Except Diagnostic Substances (Biotech) | 94.10 | 3.09 |
| 28 |
|
GNLX / Genelux Corporation | Pharmaceutical Preparations | 125.79 | 3.05 |
| 29 |
|
OVID / Ovid Therapeutics Inc.
Ovid Therapeutics Inc., based in the United States, operates within the biopharmaceutical industry and is primarily engaged in developing therapies that target rare neurological disorders. The company's research pipeline includes several innovative projects focusing on addressing significant unmet medical needs. A key project is the development of OV101 (gaboxadol), a treatment aimed at conditions such as Angelman syndrome and Fragile X syndrome, leveraging its potential to modulate GABA receptors in the brain. Another significant endeavor involves their collaboration on developing OV329, a GABA aminotransferase inhibitor, for treatment-resistant epilepsy. Ovid Therapeutics continues to collaborate with academic and corporate entities, aiming to push the boundaries of neuroscience and improve the quality of life for patients with debilitating neurological conditions. |
Pharmaceutical Preparations | 87.11 | 3.00 |
| 30 |
|
UONE / Urban One, Inc. | Radio Broadcasting Stations | 41.66 | 2.98 |
| 31 |
|
AURA / Aura Biosciences, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 401.60 | 2.96 |
| 32 |
|
RAPP / Rapport Therapeutics, Inc. | 523.38 | 2.87 | |
| 33 |
|
LAB / Standard BioTools Inc.
Standard BioTools Inc., based in the United States, operates within the biotechnology sector, focusing primarily on providing innovative tools and technologies that facilitate the analysis of biological systems. The company specializes in developing platforms that integrate tools such as mass cytometry and automated microfluidics, offering comprehensive solutions for protein and nucleic acid analysis. A key aspect of their project portfolio includes the advanced mass cytometry system, designed to enhance cellular analysis at the proteomic level, which has significant implications for research in oncology, immunology, and other fields. Standard BioTools places a strong emphasis on pushing the boundaries of molecular diagnostics, aiming to foster advancements in personalized medicine and clinical decision-making. Through its collaborative approach, the company works to establish strategic partnerships and expand its global market presence, significantly shaping the landscape of biotechnological tools and analytics. |
492.74 | 2.82 | |
| 34 |
|
KYTX / Kyverna Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 170.26 | 2.78 |
| 35 |
|
BRFS / BRF S.A. - Depositary Receipt (Common Stock)
BRF S.A., headquartered in Brazil, stands as one of the giants in the global food industry, primarily focusing on the production and sale of poultry, pork, beef products, and processed foods. The company is a leading exporter, prominently positioning itself in the Middle East, Asia, and Europe. BRF has undertaken significant sustainability projects, striving to enhance its environmental responsibility and operational efficiency. Notable initiatives include investing in feed efficiency to reduce greenhouse gas emissions and implementing water resource management practices across its operations. Furthermore, BRF continuously pursues innovation in food safety and quality, ensuring compliance with international standards and improving competitive advantage in the rapidly evolving food market. |
Meat Packing Plants | 2.76 | |
| 36 |
|
KRMD / KORU Medical Systems, Inc. | Surgical and Medical Instruments and Apparatus | 187.05 | 2.73 |
| 37 |
|
WYY / WidePoint Corporation | Computer Integrated Systems Design | 46.66 | 2.72 |
| 38 |
|
ASST / Asset Entities Inc.
Asset Entities Inc. is a US company that provides social media marketing services on platforms such as Discord and TikTok. |
Finance Services | 75.03 | 2.71 |
| 39 |
|
SOGP / Sound Group Inc. - Depositary Receipt (Common Stock) | 137.16 | 2.58 | |
| 40 |
|
LRMR / Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing on the development of novel therapeutics for complex rare diseases. A key project of Larimar is their investigational therapy, CTI-1601, which is being developed as a potential treatment for Friedreich’s ataxia, a rare genetic neuromuscular disorder. This proprietary treatment involves a fusion protein designed to deliver human frataxin, the deficient protein in patients with Friedreich’s ataxia, which is essential for mitochondrial function. Larimar’s strategic approach combines rigorous scientific research with targeted clinical trials, aiming to address significant unmet medical needs in the rare disease space, thereby positioning itself as a pioneer in therapeutic innovation. |
Pharmaceutical Preparations | 251.95 | 2.51 |
| 41 |
|
MBX / MBX Biosciences, Inc. | 387.99 | 2.49 | |
| 42 |
|
TEAD / Teads Holding Co. | Computer Programming, Data Processing, And Other Computer Related Services | 154.32 | 2.45 |
| 43 |
|
SVRA / Savara Inc.
Savara Inc. is a specialty pharmaceutical company based in the United States, primarily engaged in the development and commercialization of novel therapies for the treatment of rare respiratory diseases. A key project for Savara is Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) intended for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). This project represents Savara's commitment to addressing unmet needs within niche patient populations by targeting the underlying causes of these conditions rather than merely managing symptoms. As of 2023, the company continues to focus on advancing its clinical development pipeline to fulfill its mission of transforming the lives of patients with serious and life-shortening respiratory diseases. |
Pharmaceutical Preparations | 782.71 | 2.44 |
| 44 |
|
SOND / Sonder Holdings Inc. | Hotels, Rooming Houses, Camps, And Other Lodging Places | 20.96 | 2.38 |
| 45 |
|
API / Agora, Inc. - Depositary Receipt (Common Stock)
Agora, Inc. is a technology firm based in Shanghai, China, specializing in real-time communication solutions. The company operates predominantly in the software and IT services industry, providing APIs that facilitate voice, video, and messaging functionality across various applications. Noteworthy among its projects is the development of the Agora Real-Time Engagement Platform, which supports a wide range of industries, including gaming, social media, and education, by enabling interactive, real-time user engagement. Agora's offerings are critical in bridging communication gaps in virtual settings, enhancing user experiences by providing reliable and scalable real-time interaction capabilities across global markets. This strategic focus positions Agora as an integral player in the dynamic digital communication technology landscape. |
Prepackaged Software | 310.28 | 2.36 |
| 46 |
|
WKSP / Worksport Ltd. | Motor Vehicle Parts and Accessories | 18.76 | 2.36 |
| 47 |
|
MLGO / MicroAlgo Inc. | Computer Programming Services | 2.36 | |
| 48 |
|
STRO / Sutro Biopharma, Inc.
Sutro Biopharma, Inc., based in the United States, operates predominantly in the biopharmaceutical industry, focusing on the design and development of innovative oncology therapeutics and biotherapeutics. The company leverages its proprietary integrated cell-free protein synthesis platform, XpressCF, to produce novel protein therapeutics that have enhanced therapeutic profiles for cancer treatments. Key projects include a variety of monoclonal antibodies and antibody-drug conjugates aimed at targeted cancer therapy, such as STRO-001 and STRO-002, which are in clinical trials targeting CD74 and folate receptor alpha, respectively. Sutro Biopharma's commitment to advancing oncology treatment options with precision underpins its ongoing research and development efforts. |
Biological Products, Except Diagnostic Substances (Biotech) | 89.38 | 2.36 |
| 49 |
|
APYX / Apyx Medical Corporation
Apyx Medical Corporation, based in the United States, operates primarily in the medical technology industry. The company focuses on advancing its proprietary Helium Plasma Technology, which is utilized in surgical procedures including skin resurfacing, coagulation, and ablation. This technology is marketed under the brand name Renuvion, designed for precise applications with minimal invasiveness. Additionally, Apyx Medical is engaged in the development and distribution of electrosurgical products and tools used across various surgical environments. A key area of their business also includes OEM manufacturing services, where they produce proprietary medical devices for other companies. Apyx Medical’s strategic initiatives and innovations are geared towards enhancing safety, efficiency, and outcomes in the medical and cosmetic surgery sectors. |
Surgical and Medical Instruments and Apparatus | 75.21 | 2.35 |
| 50 |
|
DCGO / DocGo Inc. | Health Services | 155.43 | 2.35 |
| 51 |
|
KPTI / Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a biopharmaceutical company based in the United States, specifically headquartered in Newton, Massachusetts. It operates primarily in the pharmaceuticals industry, focusing on the discovery, development, and commercialization of novel therapies for the treatment of cancer and other major diseases. Key among its projects is the development of Selinexor, a first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, which has shown potential in treating multiple cancer types. The company has successfully advanced this compound through various clinical trials, leading to its FDA approval for specific oncological applications. Karyopharm continues to expand its research on SINE technology to explore therapeutic potentials across a diverse range of diseases. |
Pharmaceutical Preparations | 57.50 | 2.32 |
| 52 |
|
MAXN / Maxeon Solar Technologies, Ltd.
Maxeon Solar Technologies, Ltd., headquartered in Singapore, operates prominently within the solar energy industry. The company is renowned for its high-efficiency solar panels and innovative photovoltaic products. As a global leader in solar innovation, Maxeon Solar Technologies focuses on the development and manufacturing of its series of Maxeon and Performance solar panels, which are recognized for their durability, efficiency, and environmental benefits. A key project demonstrating Maxeon's capabilities includes supplying advanced solar panels for large-scale renewable energy installations worldwide, aiding in significant carbon footprint reductions across diverse regions. The company's strategic endeavors in pushing the boundaries of solar technology accentuate its commitment to advancing solar energy infrastructures globally while aiming for sustainability and energy security. |
Semiconductors and Related Devices | 67.48 | 2.29 |
| 53 |
|
BDSX / Biodesix, Inc. | Medical Laboratories | 63.81 | 2.28 |
| 54 |
|
SEAT / Vivid Seats Inc. | Miscellaneous Amusement And Recreation | 103.89 | 2.25 |
| 55 |
|
WBX / Wallbox N.V. | 2.25 | ||
| 56 |
|
DNTH / Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing primarily on developing innovative therapeutic solutions. The company is dedicated to advancing the field of immunology, with a significant emphasis on designing and commercializing novel treatments meant to address autoimmune and inflammatory diseases. Key projects include the development of targeted therapies that aim to modulate the immune system in a precise manner, thereby offering potential benefits over traditional treatments with fewer side effects and improved efficacy. Dianthus Therapeutics leverages cutting-edge research and technology to build a robust pipeline of drug candidates, positioning it as a formidable player in the medical research arena focused on transformative healthcare solutions. |
Pharmaceutical Preparations | 852.36 | 2.24 |
| 57 |
|
LVWR / LiveWire Group, Inc.
LiveWire Group, Inc., based in the United States, operates primarily in the electric vehicle industry, focusing on the production and distribution of electric motorcycles. As a subsidiary of Harley-Davidson, LiveWire is positioned uniquely to leverage advanced technology and an established brand name within the niche of electric motor sports. Notably, LiveWire has spearheaded initiatives such as the launch of the first electric motorcycle, LiveWire ONE, which emphasizes performance blended with sustainable mobility solutions. The company aims to expand its market share and influence in electric vehicle technology by innovating in design, consumer experience, and performance metrics, reinforcing its footprint in an increasingly eco-conscious market. |
Motorcycles, Bicycles, and Parts | 722.74 | 2.23 |
| 58 |
|
CLLS / Cellectis S.A. - Depositary Receipt (Common Stock)
Cellectis S.A. is a biopharmaceutical company based in Paris, France. It operates within the biotechnology industry, focusing on developing innovative gene-editing technologies to treat severe diseases. The company's primary projects revolve around utilizing TALEN, a proprietary gene-editing technology, to develop immunotherapies for cancer treatment. |
Biological Products, Except Diagnostic Substances (Biotech) | 2.22 | |
| 59 |
|
RDNW / RideNow Group, Inc.
RumbleOn is an e-commerce company using technology to aggregate and distribute pre-owned automotive and powersport vehicles to and from both consumers and dealers. |
Computer Programming Services | 151.38 | 2.21 |
| 60 |
|
CLSD / Clearside Biomedical, Inc.
Clearside Biomedical, Inc., based in the United States, operates within the biopharmaceutical industry, primarily focusing on the development of innovative therapies for eye diseases. The company's groundbreaking approach involves using their proprietary SCS Microinjector to deliver medication directly to the suprachoroidal space, targeting diseases such as uveitis, retinal vein occlusion, and diabetic macular edema. Key projects include XIPERE, a treatment for macular edema associated with uveitis, which exemplifies their commitment to addressing unmet medical needs in ophthalmology. This strategic focus on targeted, site-specific administration of therapeutics represents a significant part of their operations and overall mission to enhance patient outcomes in the realm of eye health. |
Pharmaceutical Preparations | 27.47 | 2.21 |
| 61 |
|
CTKB / Cytek Biosciences, Inc.
Cytek Biosciences, Inc., based in the United States, operates primarily within the biotechnology sector, focusing on advancing the capabilities of flow cytometry technologies. The company is renowned for its pioneering work in developing and manufacturing full-spectrum flow cytometry systems that provide high-resolution analysis of biological cells, significantly aiding scientific and medical research. Key projects include the development of their flagship products, the Aurora and Northern Lights systems, which offer innovative solutions for detailed cell analysis across various applications including immunology, disease research, and clinical diagnostics. Cytek's continuous innovation in high-parameter cytometric analysis demonstrates its commitment to enhancing cellular exploration and supporting the progression of personalized medicine. |
Laboratory Analytical Instruments | 510.65 | 2.20 |
| 62 |
|
GORO / Gold Resource Corporation
Gold Resource Corporation is a mining company based in the United States, principally engaged in the production and development of gold and silver. The company operates primarily in the Americas, with significant projects including the Aguila Project and the Alta Gracia Project in Mexico. These projects focus on both underground and surface mining, extracting gold, silver, as well as base metals such as copper, lead, and zinc, which are subsequently processed to produce concentrates. Gold Resource Corporation has established a reputation for cost-efficient operations and maintaining high environmental and safety standards, aiming to generate substantial shareholder value through efficient production practices, exploration, and asset acquisition strategies. |
Gold And Silver Mining | 102.75 | 2.19 |
| 63 |
|
FBRX / Forte Biosciences, Inc.
Forte Biosciences, Inc., based in the United States, operates within the biotechnology sector, focusing specifically on the development of dermatology therapies. The company pioneers innovative treatments for inflammatory skin diseases, aiming to address unmet medical needs. Key projects include their leading program, FB-401, which is a live biotherapeutic for the treatment of inflammatory skin conditions such as atopic dermatitis. The development of FB-401 reflects Forte Biosciences' commitment to leveraging cutting-edge scientific research to improve patient outcomes in dermatological conditions. The company's strategic initiatives prioritize robust clinical trials and the pursuit of novel therapeutic pathways, aiming to provide groundbreaking solutions in the realm of dermatological healthcare. |
Pharmaceutical Preparations | 200.69 | 2.18 |
| 64 |
|
NEON / Neonode Inc. | Electronic Components, Not Elsewhere Classified | 85.70 | 2.18 |
| 65 |
|
BLRX / BioLineRx Ltd. - Depositary Receipt (Common Stock)
BioLineRx Ltd. is a biopharmaceutical development company based in Israel, primarily engaged in identifying, in-licensing, and then developing promising therapeutic candidates, particularly in the oncology sector. The company focuses on advancing a portfolio of cancer therapy projects, with a notable project including Motixafortide, which targets hematological cancers and solid tumors through stimulation of the immune system and other mechanisms. Additionally, BioLineRx is working on AGI-134, a synthetic alpha-Gal immunotherapy for solid tumors that works by harnessing the body’s immune system to target and attack the treated tumor. These projects exemplify the company's commitment to innovating within the therapeutics space, aiming to address unmet medical needs in critical care areas. |
Pharmaceutical Preparations | 2.16 | |
| 66 |
|
MLTX / MoonLake Immunotherapeutics | Pharmaceutical Preparations | 3,773.54 | 2.16 |
| 67 |
|
FENC / Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is based in Canada and operates primarily in the biotechnology industry, specializing in the development of therapies that aim to treat cancer and related diseases. A key project of Fennec Pharmaceuticals has been the development of PEDMARK™, a sodium thiosulfate formulation designed to reduce the incidence of cisplatin-induced hearing loss in children and adults receiving platinum-based chemotherapy. PEDMARK™ has shown promise in clinical trials, receiving breakthrough therapy designation from regulatory authorities for its potential to address this significant side effect of cancer treatment. The company’s strategic focus on advancing treatments that contribute to oncology supportive care underlines its commitment to enhancing quality of life for cancer patients through innovative medical solutions. |
Biological Products, Except Diagnostic Substances (Biotech) | 245.95 | 2.15 |
| 68 |
|
HEPS / D-Market Elektronik Hizmetler ve Ticaret A.S. - Depositary Receipt (Common Stock)
D-Market Elektronik Hizmetler ve Ticaret A.S., operating primarily out of Turkey, is an e-commerce company engaged in providing a wide range of products and services via its integrated online retail and marketplace platforms. The company, commonly known as Hepsiburada, operates across various sectors, including electronics, fashion, home and garden, and health and beauty. Key projects under its banner focus on enhancing user experience and digital reach, such as the development of advanced logistics solutions and mobile applications to streamline the shopping process. Hepsiburada is also noted for its initiatives aimed at empowering local vendors by integrating them into the digital economy, thereby broadening their market access. |
Catalog and Mail-Order Houses | 881.18 | 2.15 |
| 69 |
|
AUTL / Autolus Therapeutics plc - Depositary Receipt (Common Stock)
Autolus Therapeutics plc is a biopharmaceutical company based in the United Kingdom, primarily engaged in the development of cancer immunotherapies. The company specializes in the engineering of CAR-T (Chimeric Antigen Receptor T-cells) therapies that are designed to target and destroy cancer cells in a patient-specific approach. A key focus of Autolus Therapeutics’ research and development portfolio is on treatments for hematological cancers, including various forms of leukemia and lymphoma. Their innovative project, AUTO1, is a notable initiative aimed at improving the safety and efficacy of CAR-T therapies for adult acute lymphoblastic leukemia. Autolus is committed to advancing these therapies through clinical trials, aiming to leverage next-generation programmed T cell therapies for sustainable cancer treatments. |
Biological Products, Except Diagnostic Substances (Biotech) | 385.90 | 2.15 |
| 70 |
|
CRD.A / Crawford & Company
Crawford & Company, based in the United States, operates primarily in the global claims management industry. The company provides a comprehensive range of services including claims adjustment, third-party claims management, and risk management solutions, aimed at improving operational efficiency and reducing cost for its clients. Crawford has developed specialized expertise in sectors such [as property and casualty insurance, along with services tailored for the automotive and healthcare industries, among others. Notable projects frequently involve large-scale claims processing following natural disasters, sophisticated risk assessments for international firms, and technological innovation like their Crawford TPA Solutions. Crawford’s operations are global, underscoring its role in facilitating business continuity and recovery in diverse markets. |
Insurance Agents, Brokers, and Service | 530.80 | 2.14 |
| 71 |
|
SKYE / Skye Bioscience, Inc. | Pharmaceutical Preparations | 123.95 | 2.08 |
| 72 |
|
ASRV / AmeriServ Financial, Inc. | National Commercial Banks | 48.73 | 2.07 |
| 73 |
|
FHTX / Foghorn Therapeutics Inc. | Pharmaceutical Preparations | 321.71 | 2.07 |
| 74 |
|
QURE / uniQure N.V. | Pharmaceutical Preparations | 985.39 | 2.06 |
| 75 |
|
NINE / Nine Energy Service, Inc.
Nine Energy Service, Inc., headquartered in the United States, is a prominent player in the oilfield services industry. Specializing in completion solutions, Nine Energy provides essential services such as onshore well completions, wireline, and production solutions for unconventional oil and gas operations. The company has a robust presence in major North American shale basins, where it executes strategic projects including well cementing, completion tools, and fracturing. True to its innovative approach, Nine Energy prioritizes technological advancements and operational efficiency to enhance well performance and client productivity, thereby solidifying its role in driving the economic feasibility and development of energy extraction. These efforts are crucial in maintaining the company’s competitive edge in a dynamic and challenging energy market. |
Oil and Gas Field Services, Not Elsewhere Classified | 28.42 | 2.03 |
| 76 |
|
ISPR / Ispire Technology Inc. | Cigarettes | 175.00 | 2.02 |
| 77 |
|
RCON / Recon Technology, Ltd.
Recon Technology, Ltd. is a Chinese company primarily engaged in the oil and gas industry, providing integrated services and equipment. It specializes in automation and enhanced oil recovery technologies designed to optimize fossil fuel production processes. Utilizing advanced software and hardware, Recon's offerings include automation system service, equipment for oil and gas extraction, and development of production techniques. One of the significant aspects of its operations involves digital oilfield solutions, which enhance decision-making processes through real-time data and analytics. Additionally, the company contributes to environmental protection by implementing technologies aimed at reducing oilfield emissions and increasing energy efficiency. Recon Technology demonstrates a pivotal support role in advancing technical efficiencies within China's robust energy sector. |
Oil and Gas Field Services, Not Elsewhere Classified | 2.00 | |
| 78 |
|
HYPR / Hyperfine, Inc. | Electromedical and Electrotherapeutic Apparatus | 92.33 | 1.99 |
| 79 |
|
ZNTL / Zentalis Pharmaceuticals, Inc. | Pharmaceutical Preparations | 126.60 | 1.98 |
| 80 |
|
IMUX / Immunic, Inc.
Immunic, Inc., based in the United States, is a biopharmaceutical company specialized in the development of treatments for chronic inflammatory and autoimmune diseases. The company, established with a focus on novel therapeutics, is actively engaged in advancing its pipeline of selective oral immunology therapies. Among its prominent projects is the development of IMU-838, a next-generation selective immune modulator that targets diseased-activated immune cells while leaving normal cells unharmed. This therapy is being explored in multiple Phase 2 and Phase 3 clinical trials for conditions such as multiple sclerosis, ulcerative colitis, and Crohn's disease. By prioritizing these potent, orally available compounds, Immunic aims to address unmet medical needs in autoimmune and inflammatory diseases. |
Pharmaceutical Preparations | 74.26 | 1.97 |
| 81 |
|
TPST / Tempest Therapeutics, Inc. | Pharmaceutical Preparations | 48.73 | 1.96 |
| 82 |
|
IFRX / InflaRx N.V.
InflaRx N.V., based in Jena, Germany, operates in the biopharmaceutical domain, primarily focusing on the development of innovative therapies for inflammatory diseases by targeting the complement system, a key element of the human immune response. The company's hallmark initiative revolves around its lead product candidate, IFX-1, an anti-C5a antibody, which shows promise across various clinical trials for treating diseases such as hidradenitis suppurativa, ANCA-associated vasculitis, and other inflammatory conditions. Furthermore, InflaRx has expanded its pipeline to explore additional compounds and targets with potential therapeutic applications in inflammatory diseases, thereby solidifying its mission to address unmet medical needs through pioneering complement-related therapeutic interventions. |
Pharmaceutical Preparations | 112.46 | 1.96 |
| 83 |
|
WOLF / Wolfspeed, Inc.
Wolfspeed, Inc., based in the United States, operates primarily in the semiconductor industry, with a specialized focus on silicon carbide and gallium nitride materials, components, and devices. These advanced materials are crucial for the production of high-performance, energy-efficient power and radio-frequency (RF) applications. Key projects for Wolfspeed involve advancing the efficiency and performance of electrical systems in sectors such as automotive (particularly electric vehicles), telecommunications, and renewable energy systems. Their innovative work supports the growing demand for sustainable energy solutions and next-generation wireless technology, positioning them as a critical player in the global effort to improve energy efficiency and expand high-speed network capabilities. |
Semiconductors and Related Devices | 193.76 | 1.96 |
| 84 |
|
WWR / Westwater Resources, Inc. | Metal Mining | 55.93 | 1.94 |
| 85 |
|
BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock)
Bicycle Therapeutics plc, headquartered in Cambridge, UK, operates primarily in the biotechnology industry and focuses on developing transformative medicines through its proprietary bicyclic peptide (Bicycle®) technology. This innovative technology platform enables the creation of new classes of therapeutics which possess the affinity and specificity typical of antibodies, coupled with the tissue penetration ability of small molecules, aimed at treating cancer and other debilitating diseases. Key projects include their lead candidates BT1718, a novel Bicycle Toxin Conjugate targeted at tumors expressing Membrane Type 1 Matrix Metalloproteinase, and BT5528, a second-generation Bicycle Toxin Conjugate aimed at the EphA2 receptor, a target associated with poor prognosis cancers. Their approach to drug development pioneers avenues in oncology, specifically using a tumor-targeted immune cell agonists strategy to activate immune responses against cancers. |
Pharmaceutical Preparations | 494.47 | 1.93 |
| 86 |
|
CPIX / Cumberland Pharmaceuticals Inc. | Pharmaceutical Preparations | 49.58 | 1.93 |
| 87 |
|
IMNM / Immunome, Inc. | Pharmaceutical Preparations | 917.12 | 1.93 |
| 88 |
|
RLMD / Relmada Therapeutics, Inc. | Pharmaceutical Preparations | 54.15 | 1.91 |
| 89 |
|
CGEM / Cullinan Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 412.63 | 1.90 |
| 90 |
|
RDI / Reading International, Inc.
Reading International, Inc., headquartered in the United States, operates as a diversified company with a primary focus on the development, ownership, and operation of entertainment and real property assets. It functions within two major sectors: cinema exhibition and real estate, including retail, commercial, and live theater assets. The company is notably engaged in the cinema business through its theaters in the United States, Australia, and New Zealand, offering a mix of films alongside enhanced cinema experiences. Key real estate projects include the redevelopment and enhancement of significant properties such as Union Square in New York and Entertainment Quarter in Sydney. These endeavors are aligned with Reading International’s strategy to leverage its cinema assets to promote real estate development, thereby integrating and enhancing value across both operational facets. |
Motion Picture Theaters | 53.11 | 1.90 |
| 91 |
|
IMMX / Immix Biopharma, Inc. | Pharmaceutical Preparations | 61.36 | 1.90 |
| 92 |
|
GTIM / Good Times Restaurants Inc. | Restaurants, Dining, and Eating Places | 17.01 | 1.89 |
| 93 |
|
MNY / MoneyHero Limited | 73.66 | 1.88 | |
| 94 |
|
RANI / Rani Therapeutics Holdings, Inc. | Pharmaceutical Preparations | 19.82 | 1.87 |
| 95 |
|
SGMO / Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc., based in the United States, operates within the biotechnology industry, specializing in genomic medicine. The company focuses on developing and commercializing transformative therapies targeting the underlying causes of genetic diseases. Key projects include gene therapy, cell therapy, and genome editing technologies. Notably, Sangamo has pioneered the application of its proprietary zinc finger nuclease (ZFN) genome editing technology, aiming to develop treatments for hemophilia and other genetic disorders. The firm actively collaborates with leading pharmaceutical companies to advance its research and clinical programs, positioning itself at the forefront of gene-edited cell therapy to potentially deliver curative treatments for severe genetic diseases. |
Biological Products, Except Diagnostic Substances (Biotech) | 149.25 | 1.86 |
| 96 |
|
BARK / BARK, Inc. | Retail Stores, Not Elsewhere Classified | 148.50 | 1.86 |
| 97 |
|
CTNM / Contineum Therapeutics, Inc. | 298.73 | 1.86 | |
| 98 |
|
UGP / Ultrapar Participações S.A. - Depositary Receipt (Common Stock)
Ultrapar Participações S.A., headquartered in Brazil, is a diversified conglomerate primarily involved in the energy and chemical sectors. The company operates through several subsidiaries, among which are Ipiranga, a major distributor of petroleum products; Ultragaz, a leading distributor of liquefied petroleum gas (LPG); and Oxiteno, a provider of specialty chemicals. These subsidiaries allow Ultrapar to maintain a robust presence in both the domestic and international markets. Noteworthy projects include Ultragaz’s initiatives in expanding LPG distribution across Brazil and Oxiteno’s advancements in sustainable chemical solutions, demonstrating Ultrapar’s strategic commitment to innovation and environmental sustainability within its industry operations. Through these key activities, Ultrapar continues to play a critical role in the energy and petrochemical sectors in Latin America. |
Natural Gas Distribution | 1.86 | |
| 99 |
|
ALEC / Alector, Inc.
Alector, Inc., based in the United States, operates primarily in the biotechnology industry, focusing on the development of therapies that harness the human immune system to combat neurodegeneration. The company's innovative approach involves targeting immune dysregulation in the brain, a key factor in neurological disorders such as Alzheimer's disease and frontotemporal dementia. Alector's pipeline includes several key projects like AL001 and AL101, both designed to enhance progranulin levels, thereby potentially modifying the course of neurodegenerative diseases. These projects are in various stages of clinical development, underlining the company's commitment to addressing some of the most challenging conditions affecting the central nervous system. |
Biological Products, Except Diagnostic Substances (Biotech) | 304.65 | 1.85 |
| 100 |
|
ARAY / Accuray Incorporated
Accuray Incorporated, based in the United States, operates primarily in the medical technology industry, specializing in the development, manufacturing, and selling of radiation therapy systems. The company's notable contributions include the CyberKnife and TomoTherapy systems, which are designed to deliver precise radiotherapy and radiosurgery treatments for cancerous and non-cancerous tumors, as well as other specified medical conditions. Accuray's innovative solutions focus on improving the accuracy and efficiency of radiation therapy, aiming to maximize patient outcomes while minimizing side effects associated with treatment. The firm's commitment to continuous innovation and global expansion has established its reputation in the precision radiation oncology field, addressing critical needs in cancer treatment worldwide. |
Surgical and Medical Instruments and Apparatus | 160.59 | 1.85 |
| 101 |
|
BCAX / Bicara Therapeutics Inc. | 657.40 | 1.84 | |
| 102 |
|
EQ / Equillium, Inc.
Equillium, Inc. is a biotechnology firm based in the United States, specifically in La Jolla, California. The company primarily focuses on developing novel products for severe autoimmune and inflammatory disorders. A key project for Equillium is itolizumab, a clinical-stage monoclonal antibody designed to modulate the immune system's activity to treat diseases driven by uncontrolled immune activation. Equillium's strategy revolves around leveraging itolizumab’s mechanism of action across various indications, including acute graft-versus-host disease, lupus nephritis, and uncontrolled asthma. This therapeutic approach positions Equillium to address significant unmet medical needs in the areas of inflammation and immune dysfunction. |
Pharmaceutical Preparations | 68.05 | 1.84 |
| 103 |
|
TMQ / Trilogy Metals Inc. | Gold And Silver Mining | 301.38 | 1.83 |
| 104 |
|
MESA / Mesa Air Group, Inc.
Mesa Air Group, Inc., based in Phoenix, Arizona, USA, operates in the aviation sector primarily as a regional air carrier. It provides feeder flights under contractual agreements with major airlines, including American Airlines and United Airlines, through its notable subsidiaries Mesa Airlines and Freedom Airlines. The company's fleet primarily consists of Bombardier CRJ900 and Embraer E175 aircraft, focusing on short-haul routes. As a key player in American regional aviation, Mesa Air Group aims to enhance operational efficiency and fleet modernization, maintaining a strategic presence in significant U.S. hubs to optimize connectivity and passenger convenience while aligning with the operational and business objectives of its mainline partners. |
Air Transportation, Scheduled | 54.00 | 1.83 |
| 105 |
|
BSGM / BioSig Technologies, Inc. | Electromedical and Electrotherapeutic Apparatus | 135.98 | 1.82 |
| 106 |
|
ANY / Sphere 3D Corp.
Sphere 3D Corp., based in Toronto, Canada, operates primarily within the technology sector, focusing on solutions that enable robust data management and desktop virtualization. The company's key initiatives revolve around empowering businesses through innovative storage and virtualization technologies underpinned by a suite of proprietary software products and hardware appliances. Sphere 3D Corp. has notably concentrated its efforts on developing cloud-compliant data solutions that enhance secure accessibility and data recovery. Its projects often intersect cutting-edge sectors such as blockchain technologies and AI-driven platforms, aiming to provide versatile and scalable solutions tailored to meet the evolving demands of digital infrastructure and data-centric applications. |
Finance Services | 18.03 | 1.82 |
| 107 |
|
CASI / CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals, Inc., based in the United States, operates within the biopharmaceutical sector, specializing in the development and commercialization of innovative therapeutics and pharmaceutical products. The company primarily focuses on cancer treatments, emphasizing a strategic approach that includes acquiring, developing, and commercializing products with a primary geographical focus on China. Among its key projects are EVOMELA®, an injection used in autologous stem cell transplant procedures for multiple myeloma patients, and a portfolio that includes several other candidates in various development stages aimed at treating a range of oncological ailments. CASI Pharmaceuticals strives to bridge Western and Chinese pharmaceutical markets, aiming to leverage regulatory and commercial strategies to expedite drug development and approval processes in these key regions. |
Biological Products, Except Diagnostic Substances (Biotech) | 36.44 | 1.81 |
| 108 |
|
OPAD / Offerpad Solutions Inc. | Real Estate Agents and Managers | 142.01 | 1.81 |
| 109 |
|
OTLK / Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., based in the United States, operates in the biopharmaceutical industry focusing on the development of complex monoclonal antibodies for various ophthalmic indications. The company's flagship project involves ONS-5010, commercially known as LYTENAVA™ (bevacizumab-vikg), which is an investigational ophthalmic formulation of bevacizumab currently undergoing clinical trials intended to secure FDA approval for the treatment of wet age-related macular degeneration. This project represents a significant advancement in therapeutic options for ocular diseases, aligning with the industry's move towards more targeted and efficacious treatment regimes. The strategic focus on innovative ophthalmic treatments positions Outlook Therapeutics as a niche player in the competitive biopharmaceutical landscape, underscoring its commitment to addressing critical unmet medical needs in the sector. |
Biological Products, Except Diagnostic Substances (Biotech) | 40.74 | 1.81 |
| 110 |
|
AREC / American Resources Corporation | Bituminous Coal And Lignite Mining | 157.23 | 1.81 |
| 111 |
|
JSPR / Jasper Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 44.28 | 1.79 |
| 112 |
|
IMMP / Immutep Limited - Depositary Receipt (Common Stock)
Immutep Limited is an Australian biotechnology company that specializes in the development of immunotherapy treatments for cancer and autoimmune diseases. Founded in 1987 and headquartered in Sydney, Immutep is at the forefront of advancing immunotherapeutic products that harness the body’s immune system. Its key projects focus on the proprietary LAG-3 (Lymphocyte Activation Gene-3) technology, which has yielded multiple product candidates, including eftilagimod alpha (IMP321), positioned as a potential enhancer of the immune response to various tumors. Additionally, Immutep’s pipeline includes multiple partnerships with major pharmaceutical companies aimed at co-developing and commercializing their immunotherapeutic compounds, demonstrating significant investment in research and potential for growth in oncology and beyond. |
Pharmaceutical Preparations | 1.79 | |
| 113 |
|
CVGI / Commercial Vehicle Group, Inc.
Commercial Vehicle Group, Inc. (CVG), based in the United States, operates predominantly in the automotive and commercial vehicle industries. The company specializes in manufacturing and supplying various products, including electrical systems, seating systems, cabin structures, controls, and other related components. CVG caters primarily to the global commercial vehicle market, serving notable heavy-duty trucks and construction equipment sectors. Key projects and initiatives typically emphasize innovation in vehicle solutions, focusing on improving driver comfort, vehicle performance, and overall safety. The company is actively involved in designing and engineering enhancements for a range of commercial applications, demonstrating a strong commitment to meeting the evolving needs of a global clientele in the commercial vehicle sphere. |
Motor Vehicle Parts and Accessories | 58.18 | 1.79 |
| 114 |
|
LTRN / Lantern Pharma Inc. | Pharmaceutical Preparations | 46.54 | 1.79 |
| 115 |
|
ATNM / Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc., based in the United States, operates within the biopharmaceutical industry and focuses on developing targeted therapies for cancers with high unmet needs. The company's principal projects center on its proprietary Antibody Radiation Conjugates (ARCs) technology, which innovatively combines the targeting ability of antibodies with the cell-killing power of radiation. A notable project is Iomab-B, an ARC intended for bone marrow transplant conditioning, currently in a pivotal Phase 3 clinical trial. Additionally, Actimab-A, another lead ARC product, targets CD33 in Acute Myeloid Leukemia (AML) and is in Phase 1/2 clinical trials. These projects exemplify the company's dedication to advancing novel treatment options for challenging oncological indications. |
Pharmaceutical Preparations | 49.76 | 1.78 |
| 116 |
|
LCUT / Lifetime Brands, Inc. | Cutlery, Handtools, And General Hardware | 95.84 | 1.78 |
| 117 |
|
NTWK / NetSol Technologies, Inc.
NetSol Technologies, Inc. is a global IT and enterprise software solutions provider headquartered in Calabasas, California, USA. Specializing primarily in the finance and leasing industry, NetSol offers a range of services including digital transformation, business consulting, and application development. A key aspect of its project portfolio is the NFS (NetSol Financial Suite) Ascent platform, which is designed to streamline asset finance and leasing operations, enhancing efficiency and automation for businesses worldwide. This platform notably supports multi-country, multi-lingual, and multi-currency transactions, making it a versatile choice for global financial institutions. Furthermore, NetSol consistently engages in technological innovation, focusing on next-generation technologies to meet evolving industry demands. The company’s strategic emphasis on research and development underpins its commitment to maintaining a competitive edge in the fintech space. |
Prepackaged Software | 48.01 | 1.77 |
| 118 |
|
RVPH / Reviva Pharmaceuticals Holdings, Inc.
Reviva Pharmaceuticals is a clinical stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular, metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine), for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. |
Pharmaceutical Preparations | 29.91 | 1.77 |
| 119 |
|
TARA / Protara Therapeutics, Inc.
Protara Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing on developing treatments for rare and specialized conditions. The company is engaged in rigorous scientific research to address unmet medical needs, particularly in oncology and rare disease sectors. Its key projects include TARA-002, an investigational therapy for lymphatic malformations, which is a primary focus of its clinical development efforts. Additionally, Protara is actively involved in the development of Intravenous (IV) Choline Chloride, a product designed to treat intestinal failure-associated liver disease (IFALD) in patients receiving parenteral nutrition. Through these projects, Protara aims to deliver novel therapeutics that significantly improve patient outcomes. |
Biological Products, Except Diagnostic Substances (Biotech) | 121.53 | 1.77 |
| 120 |
|
NFE / New Fortress Energy Inc.
New Fortress Energy Inc. is based in the United States and operates primarily in the energy sector, focusing on global integrated gas-to-power solutions. The company specializes in financing, building, and operating natural gas infrastructure and logistics to deliver fully integrated, turnkey energy solutions aimed at reducing costs and environmental impact for customers worldwide. Key projects include the development of LNG terminals and infrastructure in markets such as Jamaica, Puerto Rico, and Brazil, highlighting its strategic approach to addressing energy needs in underserved regions. By leveraging LNG and facilitating the transition towards cleaner energy sources, New Fortress Energy plays a pivotal role in reshaping how energy is produced and consumed in developing areas. |
Natural Gas Distribution | 673.55 | 1.77 |
| 121 |
|
LUNG / Pulmonx Corporation
Nippon Steel Nisshin Co., Ltd., based in Japan, operates within the primary industry of steel production, distinguished as one of the largest steel producers in the world. Embodying a legacy of innovation and quality, the company focuses on a broad spectrum of steel products including specialty steel, sheets, and pipes. Key projects and initiatives under Nippon Steel Nisshin have traditionally centered around advancing technological integration in steel manufacturing processes, enhancing environment-friendly production methods, and pursuing global competitive edges through strategic alliances and expansions. The company plays a crucial role in driving the infrastructure and automotive sectors, amongst others, by providing high durability and precision-engineered steel products. |
Surgical and Medical Instruments and Apparatus | 70.15 | 1.76 |
| 122 |
|
CXAI / CXApp Inc. | Prepackaged Software | 14.50 | 1.75 |
| 123 |
|
NXDT / NexPoint Diversified Real Estate Trust
NexPoint Diversified Real Estate Trust, based in the United States, operates within the real estate sector focusing on diversified investment strategies. The trust engages in investing directly or indirectly through property ownership or loans secured by real estate across a variety of sectors such as residential, office, and hospitality. One of its key projects includes investments in multifamily properties and opportunistic real estate endeavors that show potential for high return on investment. The trust’s strategy involves leveraging the extensive real estate expertise of its management team to capitalize on undervalued or underperforming assets, enhancing them through targeted value-add initiatives, and implementing efficient operational strategies to maximize income and asset value. |
Real Estate Investment Trusts | 179.25 | 1.75 |
| 124 |
|
TYRA / Tyra Biosciences, Inc. | Pharmaceutical Preparations | 673.40 | 1.75 |
| 125 |
|
BRLT / Brilliant Earth Group, Inc. | Jewelry, Silverware, And Plated Ware | 41.15 | 1.74 |
| 126 |
|
AIRJ / AirJoule Technologies Corporation | 271.49 | 1.73 | |
| 127 |
|
SUIG / SUI Group Holdings Limited | Finance Services | 37.65 | 1.73 |
| 128 |
|
XNCR / Xencor, Inc. | Pharmaceutical Preparations | 609.59 | 1.72 |
| 129 |
|
CCCC / C4 Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 193.14 | 1.72 |
| 130 |
|
KLXE / KLX Energy Services Holdings, Inc.
KLX Energy Services Holdings, Inc., headquartered in the United States, operates primarily within the oilfield services industry, providing a comprehensive range of technical solutions and services to the onshore oil and gas exploration sector. The company specializes in delivering products and services that support the entire lifecycle of an oilfield, from drilling and evaluation through production, maintenance, and enhancement. Key offerings include directional drilling, wellbore placement, and advanced completion solutions, enabling operational efficiency and cost-effectiveness for clients navigating the complex oil and gas market. KLX Energy Services aims to leverage its technical expertise and industry knowledge to foster technological advancements and sustainable practices within the sector. |
Oil and Gas Field Services, Not Elsewhere Classified | 33.91 | 1.71 |
| 131 |
|
FATE / Fate Therapeutics, Inc.
Fate Therapeutics, Inc., based in the United States, operates primarily within the biopharmaceutical sector, focusing on the development of programmed cellular immunotherapies for cancer and immune disorders. The company’s technology is built on harnessing the biological prowess of immune cells, including natural killer (NK) cells and T cells, among others, from induced pluripotent stem cells (iPSCs). This innovative approach enables the mass production of off-the-shelf, multipotent cell-based treatments. Fate Therapeutics is actively advancing a diverse pipeline of cellular immunotherapies, leading projects that include several in clinical trials aiming to address both hematologic malignancies and solid tumors. The company has established strategic collaborations with major entities to enhance resource sharing and development capabilities in its cutting-edge research areas. |
Biological Products, Except Diagnostic Substances (Biotech) | 114.66 | 1.70 |
| 132 |
|
OPEN / Opendoor Technologies Inc.
Opendoor Technologies Inc., based in the United States, operates primarily in the real estate industry, specifically within the domain of digital platforms for residential real estate. Founded in 2014, the company has revolutionized the traditional real estate model by offering an online marketplace that enables quick buying and selling of homes. Opendoor's platform simplifies the real estate transaction process by providing instant cash offers to sellers, thereby eliminating lengthy closing times and uncertainties typical in conventional real estate transactions. The company leverages a combination of technology, data analytics, and machine learning to assess property values accurately and streamline real estate transactions, making it a key player in the tech-driven evolution of the real estate market. |
Real Estate Agents and Managers | 4,871.06 | 1.70 |
| 133 |
|
BSBR / Banco Santander (Brasil) S.A. - Depositary Receipt (Common Stock)
Banco Santander (Brasil) S.A., based in Brazil, operates as a subsidiary of the global banking group, Banco Santander, S.A., originating from Spain. Positioned prominently in the financial services sector, the bank engages in various activities, including retail banking, direct banking, commercial banking, and asset management. It catandidates facilities to both individuals and corporate clients extending services such as loans, credit cards, and savings products, alongside investment and insurance solutions. Its significant emphasis on digital innovation led to the development of the Superdigital platform, aimed at broadening financial inclusivity by providing banking services across the digital divide. Banco Santander (Brasil) stands out for its focus on sustainable banking initiatives, integrating financial products with environmental and social responsibility, enhancing its corporate marketability in emerging economies. |
Commercial Banks, Not Elsewhere Classified | 40,716.78 | 1.70 |
| 134 |
|
PRPH / ProPhase Labs, Inc. | Pharmaceutical Preparations | 14.68 | 1.69 |
| 135 |
|
CABA / Cabaletta Bio, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 154.55 | 1.69 |
| 136 |
|
BNC / CEA Industries Inc. | 16.67 | 1.69 | |
| 137 |
|
CAN / Canaan Inc. - Depositary Receipt (Common Stock)
Canaan Inc., headquartered in China, is a prominent player in the technology sector, primarily specialized in the research, development, and sales of integrated circuit final system products, including application-specific integrated circuits (ASIC). These specialized chips are heavily utilized in cryptocurrency mining, with the company being among the pioneers in developing ASICs tailored for blockchain mining operations. Canaan Inc. has solidified its presence by expanding its offerings to include AI chip solutions, further diversifying its technological impact. The company’s most notable endeavors include establishing reliable supply chains for its advanced hardware and venturing into AI-driven applications, which synergistically enhance its core operations in the cryptocurrency mining field. |
Finance Services | 351.08 | 1.68 |
| 138 |
|
CNTA / Centessa Pharmaceuticals plc - Depositary Receipt (Common Stock) | Pharmaceutical Preparations | 2,102.44 | 1.68 |
| 139 |
|
DAIO / Data I/O Corporation | Instruments for Measuring and Testing of Electricity and Electrical Signals | 30.28 | 1.67 |
| 140 |
|
GYRE / Gyre Therapeutics, Inc.
Gyre Therapeutics, Inc., based in the United States, operates primarily in the biotechnology industry, focusing on developing innovative gene therapies. The company dedicates itself to advancing treatments for various genetic disorders, leveraging cutting-edge technology to enhance both delivery mechanisms and the precision of gene editing. A notable project involves their pioneering work on CRISPR-based therapies, designed to correct genetic defects at the molecular level. As of the last review, Gyre Therapeutics has been actively engaged in preclinical trials, aiming to address unmet medical needs within the genetic disease treatment landscape, thereby positioning itself as a potential leader in the field of genetic medicine. The company's strategic research initiatives and partnerships amplify its potential for significant contributions to gene therapy. |
Pharmaceutical Preparations | 702.06 | 1.67 |
| 141 |
|
QVCGA / QVC Group Inc.
Qurate Retail, Inc., headquartered in the United States, operates as a prominent player in the video and online commerce industries. The company harnesses its platforms to offer a wide range of consumer products, from fashion to electronics. By leveraging its proprietary technologies in video commerce across TV networks and online platforms, Qurate Retail, Inc. actively shapes an immersive shopping experience. Its key projects include enhancing digital engagement through advanced data analytics and expanding global reach with localized content, aiming to blend retail, media, and social interaction seamlessly. As of its recent strategy, Qurate Retail, Inc. focuses on maximizing customer value through innovative product curation and personalized shopping experiences, adapting to the rapidly evolving digital retail landscape. |
Catalog and Mail-Order Houses | 107.45 | 1.67 |
| 142 |
|
VTGN / Vistagen Therapeutics, Inc. | Pharmaceutical Preparations | 103.66 | 1.67 |
| 143 |
|
IZEA / IZEA Worldwide, Inc.
IZEA Worldwide, Inc., based in the United States, is a prominent player in the influencer marketing industry. The company provides a comprehensive platform that facilitates the connection between brands and content creators, fostering partnerships that enable impactful social media campaigns. Key projects and services include IZEAx, an influencer marketing platform designed to streamline the process of content creation and distribution, and BrandGraph, which offers analytics and insights into social content performance and industry trends. IZEA Worldwide, Inc. serves a diverse range of clients, from small businesses to large enterprises, helping them harness the power of influencer relationships in the digital marketing space. |
Advertising | 60.04 | 1.66 |
| 144 |
|
CERS / Cerus Corporation
Cerus Corporation, based in the United States, operates predominantly in the biotechnology sector, focusing on the development and commercialization of the INTERCEPT Blood System. This innovative system is designed to enhance blood safety by reducing the risk of transfusion-transmitted infections through the inactivation of pathogens present in donated blood. The primary technologies involved target platelets, plasma, and red blood cells, catering to a global need for safe blood supplies for transfusions. Cerus' key projects center around expanding the adoption of the INTERCEPT treatment system across blood centers worldwide, while continuously advancing research to broaden its applicability to more blood components and meet various regulatory standards for transfusion medicine. The company's efforts extend into multiple international markets, emphasizing both technological innovation and strategic partnerships to drive broader utilization and acceptance of their blood safety technologies. |
Surgical and Medical Instruments and Apparatus | 253.85 | 1.66 |
| 145 |
|
CAPR / Capricor Therapeutics, Inc.
Capricor Therapeutics, Inc., headquartered in the United States, operates primarily in the biotechnology sector. It focuses on the development of biological therapies for diseases with unmet medical needs, including rare disorders such as Duchenne muscular dystrophy (DMD) and other conditions involving cardiac and skeletal muscle deterioration. A key project involves its lead candidate, CAP-1002, which consists of allogeneic cardiosphere-derived cells aimed at modulating the body's immune response and facilitating muscle regeneration. The company's innovative approach highlights its dedication to addressing pivotal health challenges by harnessing the therapeutic potential of cell and exosome technology, which has placed it at the forefront of regenerative medicine and treatment of muscle-related diseases. |
Pharmaceutical Preparations | 309.01 | 1.66 |
| 146 |
|
HBIO / Harvard Bioscience, Inc.
Harvard Bioscience, Inc., based in the United States, operates prominently within the life sciences industry. Specializing in the development, manufacture, and sale of a wide range of specialized products, the company primarily caters to the research needs of scientific and clinical communities. Key products include fluidics systems, apparatus for molecular biology research, and instruments for animal physiology procedures. Harvard Bioscience is known for its strong emphasis on innovation and collaboration in the fields of drug discovery, regenerative medicine, and biotechnology research. It engages in ongoing projects aimed at enhancing the capabilities of its offerings, furthering its reach into global markets, and addressing the dynamic demands of biomedical research infrastructure. |
Laboratory Analytical Instruments | 21.37 | 1.66 |
| 147 |
|
UP / Wheels Up Experience Inc. | Air Transportation, Nonscheduled | 1,492.35 | 1.66 |
| 148 |
|
CDLX / Cardlytics, Inc.
Cardlytics, Inc. is a U.S.-based technology company primarily operating in the digital advertising industry. Founded in 2008 and headquartered in Atlanta, Georgia, Cardlytics leverages a proprietary platform that integrates with financial institutions to offer targeted marketing solutions based on customer spending data. The company partners with major banks to harness rich transaction streams, utilizing this data to provide marketers with the opportunity to deliver relevant advertising content directly to consumers. Key projects focus on transforming transaction data into actionable insights, promoting offers through a network of financial institutions, and improving marketing efficacy. Overall, Cardlytics aims to bridge the gap between advertisers and consumers through its data-driven marketing platform, fostering more personalized and efficient consumer engagements. |
Computer Programming, Data Processing, And Other Computer Related Services | 49.81 | 1.65 |
| 149 |
|
IVVD / Invivyd, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 135.76 | 1.64 |
| 150 |
|
ALTI / AlTi Global, Inc. | Miscellaneous Chemical Products | 422.52 | 1.64 |
| 151 |
|
BDTX / Black Diamond Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 166.68 | 1.63 |
| 152 |
|
SGHT / Sight Sciences, Inc. | Surgical and Medical Instruments and Apparatus | 192.00 | 1.63 |
| 153 |
|
KVHI / KVH Industries, Inc. | Radio and Television Broadcasting and Communications Equipment | 116.37 | 1.63 |
| 154 |
|
TLRY / Tilray Brands, Inc.
Tilray Brands, Inc. is a global leader in the production and distribution of cannabis and cannabinoid products, including medical and recreational use. The company focuses on innovation and market expansion to deliver high-quality, reliable products to consumers and patients worldwide. |
Medicinal Chemicals and Botanical Products | 1,254.53 | 1.62 |
| 155 |
|
FSP / Franklin Street Properties Corp.
Franklin Street Properties Corp., based in the United States, primarily operates within the real estate sector focusing on investment and asset management. Specializing in office properties, the company strategically invests in urban and suburban locations and is known for its portfolio of commercial spaces designed to meet the high demands of small and medium-sized growth companies. Significant activities involve both direct ownership and partnerships through asset-backed investments, with an emphasis on sustainable and profitable growth. Franklin Street Properties Corp. actively manages these assets by employing a keen strategy on property improvements and aggressive marketing to enhance property values and secure high rental occupancy rates, pivoting efficiently to adapt to changing market conditions. |
Real Estate Investment Trusts | 174.72 | 1.62 |
| 156 |
|
OBIO / Orchestra BioMed Holdings, Inc. | Surgical and Medical Instruments and Apparatus | 107.04 | 1.62 |
| 157 |
|
JBIO / Jade Biosciences, Inc. | 253.18 | 1.62 | |
| 158 |
|
ALTS / ALT5 Sigma Corporation
JanOne Inc. is a United States-based company engaged primarily in the waste management industry, focusing on specialized sectors such as recycling electronics and disposing of hazardous waste materials in an environmentally responsible manner. In addition to its mainline waste management activities, JanOne has recently undertaken projects in the pharmaceutical sector, targeting the development and distribution of non-addictive painkillers. This strategic diversification is part of their broader objective to combat the ongoing opioid crisis in the U.S. by providing safe and effective treatment alternatives. JanOne's innovative approach in both its core and extended business lines illustrates its commitment to addressing critical environmental and social challenges through sustainable business practices and medical advancements. |
Pharmaceutical Preparations | 90.01 | 1.62 |
| 159 |
|
TNYA / Tenaya Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 218.62 | 1.61 |
| 160 |
|
CRBU / Caribou Biosciences, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 174.61 | 1.61 |
| 161 |
|
NA / Nano Labs Ltd
Nano Labs Ltd. is a China-based technology company specializing in the development and production of high-performance computing chips and related technology solutions. The company focuses on integrated circuit (IC) design, primarily for use in applications such as blockchain mining, artificial intelligence (AI), and data centers. Nano Labs leverages advanced technology to create energy-efficient chips that support high computing power, catering to the growing demand for digital infrastructure in industries like cryptocurrency mining and cloud computing. |
Semiconductors and Related Devices | 113.62 | 1.60 |
| 162 |
|
ENIC / Enel Chile S.A. - Depositary Receipt (Common Stock) | Electric Services | 255,570.43 | 1.60 |
| 163 |
|
FBIO / Fortress Biotech, Inc.
Fortress Biotech, Inc., based in the United States, operates predominantly within the biopharmaceutical sector, focusing on the development and commercialization of novel pharmaceutical therapies. The company's business model hinges on developing partnerships with the biotechnology industry, leveraging their expertise to establish and support a diverse portfolio of project subsidiaries. Key projects typically involve the innovation of treatment options for rare diseases and hard-to-treat conditions, highlighting Fortress Biotech's commitment to addressing unmet medical needs. Their strategic approach integrates in-licensing, developing, and potentially commercializing cutting-edge therapeutic products, often navigating through the complex regulatory landscapes that characterize the pharmaceutical industry. |
Pharmaceutical Preparations | 110.09 | 1.60 |
| 164 |
|
LASE / Laser Photonics Corporation | Miscellaneous Electrical Machinery, Equipment, and Supplies | 29.12 | 1.60 |
| 165 |
|
MBOT / Microbot Medical Inc.
Microbot Medical Inc., headquartered in the United States, operates within the biomedical industry, specifically focusing on the design and development of micro-robotic medical technologies. The company is dedicated to advancing the field of microsurgery by creating and implementing robotic systems that facilitate highly precise surgical interventions. A key project that exemplifies their initiative is the development of the Self-Cleaning Shunt (SCS) for the treatment of hydrocephalus and Normal Pressure Hydrocephalus (NPH), which aims to prevent shunt occlusion, a common complication in such conditions. Another significant innovation is their LIBERTY Robotic System, engineered to provide endovascular surgeons with greater precision and control during interventions, striving to reduce procedure times and enhance clinical outcomes in peripheral, cardiovascular, and neurovascular procedures. These projects demonstrate Microbot Medical Inc.'s core mission to revolutionize minimally invasive surgeries through innovative robotic solutions. |
Surgical and Medical Instruments and Apparatus | 139.41 | 1.60 |
| 166 |
|
OMEX / Odyssey Marine Exploration, Inc.
Odyssey Marine Exploration, Inc. is a deep-ocean exploration company based in the United States that specializes in the discovery, development, and extraction of deep-water minerals. The company is a pioneer in the field of seafloor mineral exploration and is engaged in various projects worldwide, with a strong focus on environmentally responsible methods. Key projects include the exploration and potential extraction of phosphate deposits off the coast of Mexico and securing mineral rights for polymetallic nodule deposits in the South Pacific. Odyssey's endeavors aim to address the growing global demand for critical minerals while maintaining sustainable practices that contribute to the preservation of marine environments. |
Water Transportation | 56.36 | 1.59 |
| 167 |
|
BNTC / Benitec Biopharma Inc.
Benitec Biopharma Inc. is a biotechnology firm based in the United States, specifically focused within the healthcare sector. The company is pioneering in the development of genetic medicines, utilizing its proprietary gene-silencing technology, ddRNAi (DNA-directed RNA interference), to create therapies that target and potentially silence disease-causing genes. Benitec's pipeline primarily addresses conditions for which conventional treatments are inadequate. Noteworthy projects include therapeutics aimed at chronic and inherited diseases, such as oculopharyngeal muscular dystrophy (OPMD) and chronic hepatitis B. These innovative gene therapy projects position Benitec Biopharma as a key player in the field of genetic medicine, striving to offer novel solutions to complex medical challenges. |
Pharmaceutical Preparations | 353.69 | 1.59 |
| 168 |
|
IRWD / Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., based in the United States, operates within the healthcare sector, specifically focusing on the development and commercialization of medicines targeting gastrointestinal diseases. A significant project undertaken by Ironwood is the development and marketing of Linzess, a leading prescription medication designed for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). The company's portfolio also includes innovative pipeline projects designed to address unmet needs within the gastrointestinal space. Ironwood Pharmaceuticals harnesses a combination of internal research and development as well as strategic partnerships, positioning itself as a prominent player in the specialty pharmaceuticals industry, continuously seeking to improve patient outcomes through novel therapeutic solutions. |
Pharmaceutical Preparations | 187.61 | 1.59 |
| 169 |
|
FKWL / Franklin Wireless Corp. | Telephone and Telegraph Apparatus | 47.96 | 1.58 |
| 170 |
|
OMER / Omeros Corporation
Omeros Corporation, based in the United States, is a biopharmaceutical company known for its innovative approaches in the development and commercialization of drugs targeting inflammation, coagulopathies, and disorders of the central nervous system. Key projects include OMS721, a lectin pathway inhibitor, used for the treatment of atypical hemolytic-uremic syndrome (aHUS) and IgA nephropathy. Omeros has also made headlines with its Omidria product, a mydriatic and anti-inflammatory used during cataract surgery or intraocular lens replacement, which enhances surgical outcomes by preventing pupil constriction and reducing postoperative pain. The company's strategic focus on novel therapeutic agents addressing critical unmet needs in the medical field marks its significant footprint in the healthcare industry. |
Pharmaceutical Preparations | 249.99 | 1.57 |
| 171 |
|
FLUX / Flux Power Holdings, Inc. | Miscellaneous Electrical Machinery, Equipment, and Supplies | 24.82 | 1.56 |
| 172 |
|
PLRX / Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing on developing therapies for fibrotic diseases—a condition characterized by excessive tissue scarring which impairs normal functioning. The company's innovative approach primarily targets the biology of fibrosis, working to halt and potentially reverse the progression of tissue scarring. Key projects include advanced clinical programs like PLN-74809, which is being investigated as a treatment for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, both of which are chronic disorders marked by progressive scarring. Their research pipeline also explores potential treatments for other fibrotic diseases, underscoring Pliant's dedication to addressing significant unmet medical needs through targeted therapeutic development. |
Pharmaceutical Preparations | 114.18 | 1.56 |
| 173 |
|
HUSA / Houston American Energy Corp.
Houston American Energy Corp., based in the United States, is a significant player in the energy sector, primarily engaged in the exploration, development, and production of natural resources, specifically oil and natural gas. The company focuses its operations mainly in the Texas and Louisiana regions, capitalizing on the prolific resource plays in these areas. A key project that underscores its strategic initiatives is its involvement in the development of assets in the Permian Basin, one of the most productive oil and gas regions in the U.S. This project, among others, highlights Houston American Energy Corp.'s commitment to leveraging advanced extraction technologies and strategic partnerships to optimize resource development and ensure sustainable growth in its sector. |
Crude Petroleum and Natural Gas | 14.06 | 1.56 |
| 174 |
|
FNGR / FingerMotion, Inc. | Prepackaged Software | 88.52 | 1.55 |
| 175 |
|
ADCT / ADC Therapeutics SA | Pharmaceutical Preparations | 399.37 | 1.55 |
| 176 |
|
CVU / CPI Aerostructures, Inc. | Aircraft Parts and Auxiliary Equipment, Not Elsewhere Classified | 31.54 | 1.55 |
| 177 |
|
CUE / Cue Biopharma, Inc.
Cue Biopharma, Inc., based in the United States, operates within the biotechnology sector, focusing primarily on developing innovative immunotherapies. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), is designed to harness the body’s intrinsic immune system without the toxicities associated with conventional treatments. Key projects include therapies targeting various cancers and autoimmune diseases. A noteworthy development stream within its oncology segment includes CUE-101, a fusion protein intended to enhance the immune system's ability to target and eliminate cancer cells expressing the HPV16 E7 protein, currently in clinical trial stages. The firm’s approach integrates strategic partnerships and advanced biotechnological tactics to craft therapies that are both effective and sustainable. |
Pharmaceutical Preparations | 59.64 | 1.54 |
| 178 |
|
DH / Definitive Healthcare Corp. | Prepackaged Software | 420.04 | 1.54 |
| 179 |
|
UAMY / United States Antimony Corporation | Primary Smelting And Refining Of Nonferrous | 537.60 | 1.54 |
| 180 |
|
QRHC / Quest Resource Holding Corporation
Quest Resource Holding Corporation, based in the United States, primarily operates in the waste management and recycling sector. The company provides solutions aimed at promoting environmental responsibility and sustainability through the management of waste streams and recycling processes. Quest Resource Holding Corporation serves a diverse client base that spans various industries including automotive, grocery, and construction, offering tailored services that encompass the recycling of materials like food waste, glass, and metals. Over the years, the company has been pivotal in developing innovative projects aimed at reducing landfill use and enhancing resource efficiency, making significant strides in advancing recycling technologies and sustainable practices in waste management. |
Refuse Systems | 37.07 | 1.54 |
| 181 |
|
KNDI / Kandi Technologies Group, Inc.
Kandi Technologies Group, Inc., based in China, operates primarily in the automotive and battery solutions industries. The company specializes in the production of electric vehicles (EVs) and EV components, distinguishing itself within the market through significant investments in innovative technologies for eco-friendly transportation. Key projects include manufacturing a range of electric cars and off-road vehicles, and developing advanced battery swapping systems. Kandi is also involved in international export, capitalizing on growing global demand for sustainable transportation solutions. The company's ongoing ventures intend to leverage technological expertise to expand its footprint in the electric mobility sector, underpinning its strategy to contribute to a reduced carbon footprint worldwide. |
Motor Vehicles and Passenger Car Bodies | 118.73 | 1.53 |
| 182 |
|
NOTE / FiscalNote Holdings, Inc.
FiscalNote Holdings, Inc., based in the United States, operates primarily within the legal technology sector, providing a platform that offers real-time legal and regulatory data, aiming to transform how global organizations manage risk and compliance issues. The company has developed a suite of software services, which includes tools for monitoring legislative and regulatory developments, stakeholder management, and issues management, designed to enhance the decision-making capabilities of corporate and governmental agencies by harnessing artificial intelligence and machine learning technologies. FiscalNote’s offerings support various entities in navigating complex, dynamically changing policymaking environments efficiently, illustrating its commitment to integrating cutting-edge technology with legal and regulatory solutions. |
Business Services, Not Elsewhere Classified | 55.75 | 1.53 |
| 183 |
|
ACTG / Acacia Research Corporation
Acacia Research Corporation, based in the United States, primarily operates within the patent licensing sector. As a facilitator of patent monetization, the company focuses on acquiring, developing, and licensing patented technologies. Acacia's model centers on partnering with patent owners, such as inventors and universities, to enforce and license their patents against entities that infringe upon them. This approach effectively assists patent owners in realizing financial gains from their intellectual property. The corporation's key projects often involve strategic litigation processes to defend patent rights, coupled with negotiations to secure licensing agreements that generate revenue for both Acacia and the patent holders they represent. These initiatives are crucial in maximizing the financial potential of intellectual assets in various technological fields. |
Patent Owners and Lessors | 318.75 | 1.53 |
| 184 |
|
GETY / Getty Images Holdings, Inc.
Getty Images, Inc. is a US-based company that primarily operates as a supplier of stock images, editorial photography, video, and music for businesses and consumers. Their content offerings range from contemporary creative imagery to news, sports, entertainment, and archival content. |
Business Services, Not Elsewhere Classified | 775.70 | 1.53 |
| 185 |
|
TRVG / trivago N.V. - Depositary Receipt (Common Stock) | Computer Processing and Data Preparation and Processing Services | 238.15 | 1.52 |
| 186 |
|
COOK / Traeger, Inc. | Household Appliances | 199.73 | 1.52 |
| 187 |
|
SOC / Sable Offshore Corp. | 2,268.20 | 1.52 | |
| 188 |
|
TNXP / Tonix Pharmaceuticals Holding Corp. | Pharmaceutical Preparations | 200.35 | 1.51 |
| 189 |
|
BRCC / BRC Inc.
BRC produces and retails military and firearms themed coffee products under the brand "Black Rifle Coffee". |
Beverages | 124.07 | 1.51 |
| 190 |
|
CRWS / Crown Crafts, Inc. | Broadwoven Fabric Mills, Cotton | 32.22 | 1.51 |
| 191 |
|
CLGN / CollPlant Biotechnologies Ltd.
CollPlant Biotechnologies Ltd., based in Israel, operates within the biotechnology sector, primarily focusing on regenerative and aesthetic medicine. The company leverages its proprietary plant-based recombinant human collagen (rhCollagen) technology for developing tissue repair products. It's known for innovative projects such as BioInks for 3D printing of tissues and organs, and Vergenix™, a line comprising wound healing and orthobiologics solutions. CollPlant's strategic collaborations with international entities aim to advance their penetration in global markets, emphasizing both the therapeutic and commercial potential of its unique technology platforms. This stride in biotechnology highlights their pioneering work in synthetic biology and tissue engineering, positioning them at the forefront of biotechnological innovations in healthcare. |
Orthopedic, Prosthetic, and Surgical Appliances and Supplies | 34.59 | 1.50 |
| 192 |
|
TONX / Verb Technology Company, Inc. | Personal Services | 15.24 | 1.50 |
| 193 |
|
ORKA / Oruka Therapeutics, Inc. | 613.07 | 1.50 | |
| 194 |
|
ELTX / Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., based in the United States, operates within the biotechnology industry, focusing primarily on developing immunotherapies for cancer treatment. The company leverages its proprietary Amphiphile technology to enhance the immune system's response against cancerous cells. A key project includes their lead product candidate, ELI-002, an investigational therapeutic vaccine targeting KRAS-driven cancers, which are prevalent and typically aggressive. This vaccine aims to stimulate robust immune responses against multiple KRAS mutations simultaneously, addressing a significant unmet need in oncology. Elicio's innovative approach in immuno-oncology underscores its commitment to advancing cancer treatments through targeted therapies and vaccine development. |
Pharmaceutical Preparations | 189.14 | 1.49 |
| 195 |
|
LPSN / LivePerson, Inc.
LivePerson, Inc., headquartered in the United States, operates primarily in the technology sector focusing on artificial intelligence and mobile messaging solutions. The company revolutionizes how businesses engage with customers through its proprietary platforms that facilitate real-time conversations via text and messaging services. A key suite of its offerings includes conversational AI, automation, and analytics tools that empower businesses to deliver enhanced customer service and increase engagement. LivePerson’s notable projects include implementing advanced chatbot solutions that integrate with major messaging services like WhatsApp and Facebook Messenger, making it instrumental in transforming customer communication dynamics across various industries, including retail, telecommunications, and finance. Through its innovative approaches, LivePerson is pivotal in helping businesses optimize customer interactions and operational efficiencies. |
Prepackaged Software | 87.46 | 1.49 |
| 196 |
|
NRXP / NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., headquartered in the United States, operates prominently within the pharmaceutical industry. The company is dedicated to pioneering novel therapies, focusing on mental health disorders and inflammatory diseases. A pivotal project undertaken by NRx Pharmaceuticals is the development of Cyclurad, a treatment designed for suicidal bipolar depression, which is an innovation underpinned by intellectual property and strategic collaborations with academic and medical institutions. Another significant initiative focuses on addressing critical care therapies for lung injury and cytokine storm syndrome related to COVID-19, demonstrating the company's commitment to responding to urgent global health crises. NRx Pharmaceuticals continues to evolve its research and clinical trials to meet complex healthcare challenges, leveraging cutting-edge science and strategic partnerships. |
Pharmaceutical Preparations | 52.98 | 1.48 |
| 197 |
|
CAAS / China Automotive Systems, Inc.
China Automotive Systems, Inc. is a prominent automotive company based in China, primarily engaged in the production and sale of automotive parts and systems, including power steering systems and other related components. Established in 2003, the company has grown substantially, serving major automotive manufacturers in China as well as international markets. Key projects typically involve the development and integration of advanced steering systems designed to enhance vehicle performance and safety. With a focus on innovation and quality, China Automotive Systems continues to expand its technology and production capabilities to meet the evolving demands of the automotive industry, maintaining a competitive edge within both domestic and global markets. |
Motor Vehicle Parts and Accessories | 132.75 | 1.47 |
| 198 |
|
LDI / loanDepot, Inc.
LoanDepot, Inc. is a United States-based company primarily operating within the nonbank consumer lending industry. Founded in 2010, it has established itself as a significant player in the mortgage and non-mortgage loan sectors, catering primarily to residential markets. The company is headquartered in Foothill Ranch, California, and has embarked on key projects focusing on leveraging technology to streamline the mortgage process. Utilizing a digital-first approach, LoanDepot successfully integrates web-based tools and data analytics to enhance customer experiences and operational efficiencies. Its services encompass mortgage lending, refinancing, and personal and home equity loans, making substantial strides in digital innovations to improve access to financial services in the housing market. |
Finance Services | 600.97 | 1.47 |
| 199 |
|
TORO / Toro Corp.
Toro Corp. is an energy transportation services company with a fleet of tanker vessels that carry crude oil and petroleum products worldwide. |
Deep Sea Foreign Transportation of Freight | 47.84 | 1.46 |
| 200 |
|
NOTV / Inotiv, Inc.
Inotiv, Inc., based in the United States, operates within the biopharmaceutical and healthcare sector, primarily focusing on providing drug discovery and development services. The company’s key offerings include nonclinical and analytical drug research, development services, and regulatory consulting, catering to clients in the pharmaceutical, biotechnology, and medical device industries. Inotiv has been actively involved in expanding its service capabilities through strategic acquisitions, such as the purchase of Envigo RMS LLC, which significantly increased its capacity in toxicology research and other preclinical services. This expansion strategy enhances Inotiv’s ability to support its clients from early-stage discovery through preclinical development, underscoring its role as a comprehensive provider in the life sciences field. |
Commercial Physical and Biological Research | 56.34 | 1.46 |
| 201 |
|
CRCA / Proshares Trust - Proshares Ultra Crcl Etf | 1.46 | ||
| 202 |
|
QTRX / Quanterix Corporation | Laboratory Analytical Instruments | 176.48 | 1.46 |
| 203 |
|
RGC / Regencell Bioscience Holdings Limited | Medicinal Chemicals and Botanical Products | 1.46 | |
| 204 |
|
ENTA / Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., headquartered in the United States, focuses primarily on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Operating within the biotechnology sector, Enanta has concentrated its efforts on key therapeutic areas, notably hepatitis C virus (HCV) where it collaborates with Abbott Laboratories, and respiratory syncytial virus (RSV), as well as other liver diseases like non-alcoholic steatohepatitis (NASH). The company leverages its expertise in chemistry-driven drug discovery to develop innovative treatments that address significant unmet medical needs. As a part of its strategic initiatives, Enanta Pharmaceuticals continues to enhance its proprietary platforms to expand its pipeline and further its research endeavors across these core areas. |
Pharmaceutical Preparations | 188.87 | 1.46 |
| 205 |
|
TRON / Tron Inc. | Blank Check | 73.91 | 1.45 |
| 206 |
|
TTGT / TechTarget, Inc. | 403.20 | 1.45 | |
| 207 |
|
IOVA / Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc., based in the United States, operates primarily within the biotechnology industry, focusing its efforts on pioneering novel cancer immunotherapies. The company is notably invested in the development of tumor-infiltrating lymphocyte (TIL) products for the treatment of patients with severe cancer conditions. Iovance's flagship projects include lifileucel for metastatic melanoma and LN-145 for cervical and head and neck cancers. These investigational therapies are designed to enhance the anti-tumor activity of patient-derived T cells by expanding and reinfusing them into the patient, a method that potentially offers a significant advancement in personalized cancer treatment. The company's dedication to transforming the treatment landscape for resistant or recurrent cancers positions it at the forefront of innovation within its field. |
Biological Products, Except Diagnostic Substances (Biotech) | 853.09 | 1.45 |
| 208 |
|
MMLP / Martin Midstream Partners L.P. - Limited Partnership | Petroleum Bulk stations and Terminals | 123.41 | 1.45 |
| 209 |
|
YSG / Yatsen Holding Limited - Depositary Receipt (Common Stock) | Perfumes, Cosmetics, and Other Toilet Preparations | 883.11 | 1.45 |
| 210 |
|
SRL / Scully Royalty Ltd.
Scully Royalty Ltd. is a diversified merchant bank headquartered in Bermuda, primarily engaged in iron ore production and merchant banking activities. The company operates through various segments, with a significant focus on the natural resources sector, where it benefits substantially from its iron ore royalty interests. A key aspect of Scully Royalty's operations is the management of its royalty income derived from the Scully Mine, located in Canada, which underpins its fiscal foundation. Additionally, the company's merchant banking division strategically invests in a variety of financial assets, emphasizing a balanced approach to asset management that aligns closely with medium to long-term investment horizons. This divisional structure allows Scully Royalty to diversify risks while capitalizing on opportunities across different sectors and regions. |
Mineral Royalty Traders | 1.45 | |
| 211 |
|
SES / SES AI Corporation | Miscellaneous Products Of Petroleum And Coal | 395.33 | 1.45 |
| 212 |
|
CNTB / Connect Biopharma Holdings Limited - Depositary Receipt (Common Stock) | Pharmaceutical Preparations | 95.04 | 1.44 |
| 213 |
|
ARCT / Arcturus Therapeutics Holdings Inc. | Pharmaceutical Preparations | 485.68 | 1.44 |
| 214 |
|
SOPH / SOPHiA GENETICS SA
SOPHiA GENETICS SA, based in Switzerland, operates primarily in the biotechnology sector, specializing in data-driven medicine and clinical genomics. The company leverages its AI-powered platform, SOPHiA, to analyze medical data and enhance the diagnostic accuracy for healthcare providers, thus enabling more targeted treatments in oncology, hereditary cancer, metabolism, pediatrics, and cardiology. A key project involves partnerships with hospitals and research institutions to improve cancer diagnostics and treatment strategies through genomic and radiomic analysis. By integrating deep learning into DNA sequencing, SOPHiA GENETICS aids in interpreting complex genetic data, promoting advancements in personalized medicine and optimizing clinical trials. With its focus on innovation in genomics, the company is central to transforming data into actionable insights in healthcare. |
Computer Processing and Data Preparation and Processing Services | 219.63 | 1.44 |
| 215 |
|
AIRG / Airgain, Inc.
Airgain, Inc., headquartered in San Diego, California, USA, operates primarily in the technology sector, focusing on the design, development, and engineering of advanced wireless communications solutions. The company specializes in antenna products, including embedded, external, and carrier-class antennas. A key provider for residential wireless local area networking, Airgain's products are instrumental in automotive, enterprise, and industrial markets. Their innovations support a range of applications from global consumer electronics to enterprise and industrial solutions. Furthermore, Airgain has strategically expanded its project portfolio by venturing into Internet of Things (IoT) products and services, underpinning the critical role of high-performance wireless connectivity in driving modern technological advancements. Their expertise in integrating antenna solutions with IoT and mobile technology facilitates robust, high-efficiency communications platforms crucial for today’s digital economy. |
Radio and Television Broadcasting and Communications Equipment | 51.78 | 1.44 |
| 216 |
|
BCAB / BioAtla, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 31.50 | 1.44 |
| 217 |
|
RCEL / AVITA Medical, Inc.
AVITA Medical, Inc., based in Valencia, California, USA, operates in the biotechnology industry, primarily focusing on regenerative medicine and skin repair. The company is renowned for its proprietary technology platform, RECELL, which facilitates the rapid creation of autologous skin cells to treat a variety of skin issues, including burns, chronic wounds, and aesthetic imperfections. AVITA's key projects revolve around expanding the therapeutic applications of the RECELL system and streamlining the treatment protocols for burn care, which has pivotal implications for significantly reducing hospital stays and improving patient recovery outcomes. The company strategically focuses on clinical research and collaborations to improve and validate its regenerative product offerings on a global scale. |
Surgical and Medical Instruments and Apparatus | 113.91 | 1.44 |
| 218 |
|
ALLO / Allogene Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 253.15 | 1.44 |
| 219 |
|
SMSI / Smith Micro Software, Inc.
Smith Micro Software, Inc., based in the United States, operates within the software industry, specializing in the development and marketing of telecommunications and graphics software. The company has made significant strides in the wireless communications sector, and offers innovative solutions designed to enhance device and network security, boost connectivity, and improve user experience across various digital platforms. Among its prominent projects are the SafePath® family solutions, which provide family location and parental controls, CommSuite® that manages voice messages and Visual Voicemail, and ViewSpot®, a retail display management platform. Smith Micro Software also has a storied history in graphic design through products like Moho®, a tool for creating 2D animations. This portfolio underscores the company’s commitment to utilizing technology to create integrated user environments across multiple digital touchpoints. |
Prepackaged Software | 14.34 | 1.43 |
| 220 |
|
AMBR / Amber International Holding Limited - Depositary Receipt (Common Stock) | Prepackaged Software | 267.11 | 1.43 |
| 221 |
|
CRML / Critical Metals Corp. | 1.43 | ||
| 222 |
|
DSGN / Design Therapeutics, Inc.
Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions. |
Pharmaceutical Preparations | 367.88 | 1.43 |
| 223 |
|
VSTM / Verastem, Inc. | Pharmaceutical Preparations | 662.61 | 1.42 |
| 224 |
|
TBI / TrueBlue, Inc. | Help Supply Services | 175.17 | 1.42 |
| 225 |
|
AIFU / AIFU Inc.
Fanhua Inc. is a financial services company based in China that primarily operates in the insurance sector. As a leading provider, the company focuses on distributing a diverse array of insurance products and services. Its offerings include property, casualty, life, and health insurance, supplied through a widespread network that includes both online platforms and offline agencies. Fanhua leverages advanced technology to enhance efficiency and customer engagement, positioning itself strongly within China's growing insurance market. The company's strategic projects often revolve around expanding its digital capabilities and reaching untapped customer segments to sustain growth and profitability in a competitive industry landscape. This continuous innovation and market penetration strategy underline Fanhua's commitment to maintaining its position as a key player in China's insurance industry. |
Insurance Agents, Brokers, and Service | 1.42 | |
| 226 |
|
KLTR / Kaltura, Inc.
Kaltura, Inc., headquartered in the United States, is a prominent player in the software and technology sector, specializing in video management and cloud TV solutions. The company provides a comprehensive suite of products designed to facilitate video hosting, streaming, and monetization, catering to a diverse clientele that includes educational institutions, media corporations, and enterprises. Key projects focus on enhancing online video experiences such as virtual classrooms, video portals, and live events, integrating advanced functionalities like AI-driven insights and analytics, customizable player designs, and robust security features. Kaltura's initiatives ensure high scalability and reliability, aiming to redefine user engagement and content delivery in a continuously evolving digital landscape. |
Prepackaged Software | 225.03 | 1.42 |
| 227 |
|
DIBS / 1stdibs.Com, Inc. | Catalog and Mail-Order Houses | 101.85 | 1.42 |
| 228 |
|
DLTH / Duluth Holdings Inc.
Duluth Holdings Inc., based in the United States, operates primarily in the retail industry, specializing in clothing and tools designed for work, outdoor, and casual wear. Founded in 1989 and headquartered in Mount Horeb, Wisconsin, the company markets its products under the Duluth Trading brand. It is known for providing durable, functional, and innovative goods that cater to the requirements of tradespeople and outdoor enthusiasts. Duluth Holdings has expanded its market presence through a blend of online and physical store strategies, establishing numerous locations across various states. Key projects include the enhancement of their e-commerce platform and expansion of their physical retail footprint to increase direct-to-consumer sales channels. |
Apparel And Accessory Stores | 131.59 | 1.41 |
| 229 |
|
BIOX / Bioceres Crop Solutions Corp.
Bioceres Crop Solutions Corp., headquartered in Rosario, Argentina, operates primarily in the agricultural biotechnology sector. The company develops and provides crop productivity solutions designed to enable the transition of agriculture towards carbon neutrality. These solutions include seed treatments, genetic improvements, and crop protection products that enhance yields while reducing environmental impact. Key projects include the development of drought-resistant crops under the HB4 technology, which represents a significant advancement in agronomic traits for vital crops such as soybeans and wheat. Through strategic partnerships and advanced biotechnological research, Bioceres aims to address critical challenges in sustainable agriculture on a global scale. |
Agricultural Chemicals | 170.82 | 1.40 |
| 230 |
|
FF / FutureFuel Corp.
FutureFuel Corp., based in the United States, operates predominantly within the chemical manufacturing industry, focusing on the development and production of diversified chemical products and bio-based fuel products. The company’s operations are primarily centered in its facility in Batesville, Arkansas. FutureFuel Corp. specializes in custom manufacturing (manufacturing chemicals for specific customers) and performance chemicals, which include products like bleach activators and proprietary herbicide and adjuvant formulations. A noteworthy aspect of its portfolio includes the production of biodiesel and biofuels, positioning it within the sustainable energy sector. FutureFuel’s strategic initiatives encompass adapting to market demands in clean energy and environmentally conscious chemical production, thus addressing both industrial customer needs and consumer-centric sustainability trends. |
Industrial Organic Chemicals | 173.46 | 1.40 |
| 231 |
|
TBLA / Taboola.com Ltd.
Taboola.com Ltd. is a digital advertising company based in Israel, specializing predominantly in providing a platform for content recommendations. It's well known for its unique model where it teams up with publishers and advertisers to deliver personalized content suggestions, often found at the bottom of articles on popular websites. Key to Taboola's operations is their proprietary algorithm which predicts interests and engagement of different audiences, thereby enhancing ad revenue for publishers while providing advertisers with targeted outreach capabilities. Their notable projects include acquisitions and partnerships with leading media companies worldwide, aimed at expanding their market presence and enhancing their technology stack to foster a more engaging user experience in the competitive internet advertising industry. |
Computer Programming, Data Processing, And Other Computer Related Services | 1,001.18 | 1.40 |
| 232 |
|
BTCM / BIT Mining Limited - Depositary Receipt (Common Stock)
BIT Mining Limited, based in China, operates primarily in the cryptocurrency sector with significant ventures into mining and related services. As a prominent player in the cryptocurrency industry, it focuses on the development and operation of cryptocurrency mining pools, particularly those involved with Bitcoin. BIT Mining has expanded its portfolio to include cryptocurrency mining data centers, demonstrating a strategic approach to leveraging global energy resources. The company has also ventured into cryptocurrency mining machine manufacturing, aiming to enhance the efficiency and profitability of its operations. Highlighting its growth and adaptability, BIT Mining continuously seeks international expansion, notably through investments in mining centers in overseas markets, thereby broadening its operational footprint and strengthening its market position. |
Finance Services | 43.14 | 1.40 |
| 233 |
|
ATHA / Athira Pharma, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 15.14 | 1.39 |
| 234 |
|
INMB / INmune Bio, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 52.37 | 1.39 |
| 235 |
|
ERAS / Erasca, Inc. | Pharmaceutical Preparations | 455.26 | 1.39 |
| 236 |
|
CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock)
COMPASS Pathways plc is a health care company based in the United Kingdom, primarily focusing on the biotechnology industry. It specializes in developing therapies that address unmet needs within mental health care. COMPASS Pathways is notably recognized for its pioneering research in psilocybin therapy and its potential applications in treatment-resistant depression. One of their key projects is COMP360, a proprietary formulation of synthetic psilocybin, now advancing through clinical trials aimed at evaluating its safety and effectiveness. The company's efforts are part of a broader aim to innovate within psychiatric treatment modalities, contributing to evidence-based solutions that can significantly impact global mental health treatment paradigms. |
Pharmaceutical Preparations | 481.50 | 1.39 |
| 237 |
|
CGC / Canopy Growth Corporation
Canopy Growth Corporation, based in Canada, operates at the forefront of the global cannabis industry. Established as a medical marijuana producer, the company has expanded its reach to include a wide array of cannabis products, including dried flower, oil, capsules, and hemp. Key projects and initiatives include their partnership with Constellation Brands to delve into cannabis-infused beverages, and significant investments in research and development to innovate and scale up their product line. The firm focuses heavily on both the recreational and medical cannabis markets, leveraging state-of-the-art growing and production facilities to maintain and enhance their market position. Canopy Growth's strategy includes expanding its international presence, particularly in regions with evolving cannabis regulations. |
Medicinal Chemicals and Botanical Products | 298.49 | 1.39 |
| 238 |
|
TBHC / The Brand House Collective, Inc.
Kirkland's, Inc., based in the United States, operates within the retail industry, specializing in home decor products. It offers a diverse range of merchandise including furniture, textiles, and various decorative accessories. Integral to its business strategy are its brick-and-mortar stores strategically located across the country, supplemented by a robust e-commerce platform that extends its market reach. Key projects have centered on enhancing digital capabilities and optimizing its supply chain to better meet consumer demands while maintaining cost efficiency. These initiatives are part of Kirkland's broader aim to improve customer experience and operational effectiveness, positioning itself competitively in a dynamic retail environment. |
Retail Stores, Not Elsewhere Classified | 38.62 | 1.39 |
| 239 |
|
UFI / Unifi, Inc. | Textile Mill Products | 82.26 | 1.39 |
| 240 |
|
BW / Babcock & Wilcox Enterprises, Inc.
Babcock & Wilcox Enterprises, Inc., headquartered in the United States, operates primarily in the power generation sector, offering a variety of services and technologies to enhance the efficiency and environmental quality of energy production. The company has historically been pivotal in the design and manufacture of boilers and nuclear components, positioning itself as a leader in clean energy projects and services that support both fossil and renewable power generation. Noteworthy projects include advancements in biomass conversion technologies and environmental equipment for clean air and water. Babcock & Wilcox continue to expand their global footprint, undertaking strategic projects that leverage their expertise in engineering, technology, and manufacturing to address the evolving demands of the energy industry. |
Heating Equipment, Except Electric and Warm Air Furnaces | 212.26 | 1.39 |
| 241 |
|
GRWG / GrowGeneration Corp. | Building Materials, Hardware, Garden Supply, And Mobile Home Dealers | 90.55 | 1.39 |
| 242 |
|
IGC / IGC Pharma, Inc.
IGC Pharma, Inc., based in the United States, operates primarily within the biotechnology sector, focusing on the development and commercialization of cannabinoid-based therapies for medical conditions that currently have limited treatment options. The company is actively engaged in pioneering research projects centered around Alzheimer’s disease and other neurological conditions. One of its notable ventures involves the formulation of IGC-AD1 (Hyblonol), which is in the clinical trial phase aimed at alleviating symptoms of Alzheimer’s. Additionally, IGC Pharma’s portfolio extends into the development of novel therapeutic agents designed to treat severe pain and seizures, supporting its position as a prominent innovator in cannabinoid pharmacology in the healthcare industry. |
Pharmaceutical Preparations | 36.35 | 1.38 |
| 243 |
|
ANIX / Anixa Biosciences, Inc.
Anixa Biosciences, Inc., headquartered in the United States, operates in the biotechnology sector, primarily focusing on the development of innovative approaches in cancer treatment and infectious disease prevention. The company is engaged in advancing a diverse portfolio of projects including proprietary cancer vaccines and therapies that modulate key immune responses. Notably, Anixa’s research initiatives target breast cancer with a vaccine designed to prevent the recurrence of triple-negative breast cancer, a particularly aggressive form of the disease. Additionally, the company explores the therapeutic potential of chimeric endocrine receptor technology. Anixa is also developing a nasal vaccine for COVID-19, highlighting its dedication to addressing significant global health challenges. The company’s projects often involve collaborations with leading academic institutions and research organizations to facilitate the transition from scientific discovery to clinical application. |
Pharmaceutical Preparations | 95.67 | 1.38 |
| 244 |
|
MFH / Mercurity Fintech Holding Inc. | 354.73 | 1.38 | |
| 245 |
|
LFWD / Lifeward Ltd. | Orthopedic, Prosthetic, and Surgical Appliances and Supplies | 8.30 | 1.38 |
| 246 |
|
INCR / InterCure Ltd. | Commercial Physical and Biological Research | 1.38 | |
| 247 |
|
BGSF / BGSF, Inc.
BGSF, Inc., based in the United States, operates primarily in the workforce solutions sector. The company specializes in providing a diverse range of staffing and consulting services across multiple industries, with a significant emphasis on real estate, professional services, and light industrial sectors. BGSF’s approach involves strategic staffing solutions, workforce management, and outsourcing services designed to address the specific needs of its clients to enhance productivity and operational efficiency. Some of their key projects include tailored workforce solutions that integrate technology and expertise to streamline client staffing processes, thereby creating significant value in sectors like property management and IT services. These initiatives position BGSF not merely as a staffing agency, but as a comprehensive partner in workforce optimization. |
Help Supply Services | 68.16 | 1.38 |
| 248 |
|
AVTX / Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc., headquartered in the United States, operates within the biotechnology industry, focusing primarily on the development of transformative therapies for serious and rare diseases. A key aspect of its project portfolio includes innovative treatments targeting conditions such as autoimmune and rare diseases, where significant unmet medical needs exist. The company employs a robust, science-driven approach that emphasizes genetic insights and novel therapeutic pathways. Avalo Therapeutics' dedication to leveraging cutting-edge science to design and develop medications positions it distinctively for advancing treatments that can substantively improve patient outcomes in underserved medical areas, aligning its strategic initiatives with long-term health solutions and likely growth in its biotechnological endeavors. |
Pharmaceutical Preparations | 125.71 | 1.38 |
| 249 |
|
MOGO / Mogo Inc.
Mogo Inc. is a fintech company based in Canada. Specializing in personal finance, Mogo offers a wide range of financial solutions aimed at enhancing consumer financial health. These solutions encompass personal loans, identity fraud protection, mortgages, a Visa Prepaid Card, and a digital payments platform. Furthermore, Mogo extends into the cryptocurrency space, providing services that allow the buying and selling of cryptocurrencies. A key project for Mogo is its climate-conscious initiative, which includes offering carbon offset credits to engage their user base in environmental sustainability. The firm strives to integrate innovative technologies with financial services, capitalizing on the growing demand for digital financial products in Canada and beyond. |
Finance Services | 43.72 | 1.37 |
| 250 |
|
HLLY / Holley Inc.
Holley Inc., based in the United States, operates primarily within the automotive aftermarket industry. The company has established itself as a prominent developer and distributor of high-performance automotive parts, serving both automotive enthusiasts and professional racers. Holley’s product portfolio extends across a range of engine-related parts including fuel injection systems, carburetors, and exhaust systems. Key projects have centered on innovations in fuel system management and the development of high-efficiency air and exhaust flow systems in engines, all designed to enhance vehicle performance and efficiency. Holley's deep-rooted engagement with motorsports and muscle cars augments its brand in competitive automotive markets, marrying tradition with cutting-edge automotive technology. |
Motor Vehicle Parts and Accessories | 460.23 | 1.37 |
| 251 |
|
KTCC / Key Tronic Corporation
Key Tronic Corporation, based in the United States, operates chiefly in the electronic manufacturing services (EMS) industry. This corporation specializes in providing integrated design, engineering, and manufacturing solutions to a diverse set of clients across various sectors, including consumer electronics, telecommunications, and industrial products. With a strong emphasis on custom engineering and a full range of services from product assembly to supply chain management, Key Tronic has established itself as a versatile player capable of managing complex manufacturing requirements. Key projects typically involve precision engineering and involve intricate production processes, underscoring the company's commitment to quality and innovation in the technology manufacturing space. |
Printed Circuit Boards | 34.22 | 1.37 |
| 252 |
|
HYFT / ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. is a biotechnology company based in Canada that specializes in the discovery and development of novel antibody-based solutions. Operating primarily in the pharmaceutical sector, the company focuses on harnessing its proprietary platforms to advance monoclonal, bispecific, and other types of antibody therapies. It engages in comprehensive service offerings, ranging from target analysis to preclinical studies, serving a global clientele in the rapidly evolving therapeutic and diagnostic antibody industry. Key projects often involve partnerships with biopharma firms to address complex diseases such as cancer and autoimmune disorders. These collaborations are crucial in accelerating the pipeline from discovery through pre-clinical phases, positioning ImmunoPrecise as a valuable player in antibody research and development. |
Pharmaceutical Preparations | 89.08 | 1.37 |
| 253 |
|
VVPR / VivoPower International PLC | Electric and Other Services Combined | 1.36 | |
| 254 |
|
GANX / Gain Therapeutics, Inc. | Pharmaceutical Preparations | 54.16 | 1.36 |
| 255 |
|
RMTI / Rockwell Medical, Inc.
Rockwell Medical, Inc., based in the United States, primarily operates within the healthcare sector, focusing on the development and marketing of innovative therapeutic products and services for patients suffering from chronic kidney disease (CKD). Central to their product lineup are dialysis concentrates, which are used in the dialysis process critical for patients undergoing treatment for end-stage renal disease (ESRD). Among their key products, Triferic, an FDA-approved iron therapy that treats iron deficiency in CKD patients, stands out. This unique therapy is administered through dialysate, directly substituting iron loss during dialysis, thereby maintaining hemoglobin without increasing iron stores, offering a distinctive approach to iron management in a dialysis setting. |
Pharmaceutical Preparations | 55.43 | 1.36 |
| 256 |
|
ZEPP / Zepp Health Corporation - Depositary Receipt (Common Stock) | Electronic Computers | 786.44 | 1.36 |
| 257 |
|
ATXS / Astria Therapeutics, Inc. | Pharmaceutical Preparations | 424.95 | 1.35 |
| 258 |
|
AREN / The Arena Group Holdings, Inc. | Cable and Other Pay Television Services | 303.46 | 1.35 |
| 259 |
|
WPRT / Westport Fuel Systems Inc. | Engines And Turbines | 43.20 | 1.35 |
| 260 |
|
DSX / Diana Shipping Inc.
Diana Shipping Inc. is a global provider of shipping transportation services, based in Athens, Greece. Founded in 1999, the company primarily operates in the dry bulk cargo sector, facilitating the marine transportation of commodities such as iron ore, coal, grain, and other materials essential for manufacturing and production. Diana Shipping Inc. focuses on owning and operating a fleet of dry bulk vessels, including Panamax, Kamsarmax, and Capesize ships. The company strategically manages its vessel investments and chartering activities to cater to the needs of the international shipping market. Diana Shipping’s operational strategy centers around maintaining a modern, high-quality fleet while leveraging its extensive industry expertise to enhance chartering services, thereby ensuring efficient and reliable transport solutions for its clientele. |
Deep Sea Foreign Transportation of Freight | 183.71 | 1.35 |
| 261 |
|
CNVS / Cineverse Corp.
Cineverse Corp., based in the United States, operates primarily within the entertainment industry, specifically focusing on digital cinema. The company has adeptly positioned itself in the provision of comprehensive digital cinema services, including distribution and event services that cater to major film studios and independent distributors. A key project for Cineverse Corp includes its involvement in advanced digital cinema technologies, emphasizing solutions for streamlined distribution and projection of movies across a broad network of theaters. This endeavor underscores the company's commitment to enhancing the cinema experience through technological innovations, thereby supporting its clientele in delivering high-quality entertainment to a global audience. |
Video Tape Rental | 63.74 | 1.35 |
| 262 |
|
NVCT / Nuvectis Pharma, Inc. | Pharmaceutical Preparations | 159.74 | 1.35 |
| 263 |
|
CCO / Clear Channel Outdoor Holdings, Inc.
Clear Channel Outdoor Holdings, Inc., based in the United States, is a prominent player in the outdoor advertising industry. The company specializes in providing a diverse array of advertising platforms including billboards, street furniture, and transit displays across global markets. Clear Channel Outdoor is noted for leveraging innovative technology and analytics to deliver tailored advertising solutions that engage public audiences effectively. Key projects often involve the development and expansion of digital billboards and smart advertising solutions that integrate real-time data to enhance advertiser impact. The firm's strategic initiatives are primarily focused on expanding their digital inventory and enhancing programmatic advertising capabilities to capitalize on modern marketing trends and increase their geographical footprint in high-growth areas. |
Advertising | 658.38 | 1.35 |
| 264 |
|
VRAR / The Glimpse Group, Inc.
The Glimpse Group, Inc., headquartered in the United States, is a diversified Virtual Reality (VR) and Augmented Reality (AR) platform company, focused on leveraging these technologies to create innovative solutions across various industries. The company's primary industry revolves around the development and commercialization of immersive technology applications, aiming to enhance user experiences in fields such as education, training, marketing, and entertainment. Key projects by The Glimpse Group typically involve the development of proprietary VR and AR software and services, often tailored to the specific needs of enterprise clients, thereby embedding advanced technological tools into the workflow of conventional businesses and educational institutions to drive engagement, efficiency, and growth. |
Computer Programming Services | 29.15 | 1.35 |
| 265 |
|
CELU / Celularity Inc. | Pharmaceutical Preparations | 58.18 | 1.35 |
| 266 |
|
PLCE / The Children's Place, Inc.
The Children's Place, Inc., based in the United States, operates within the retail industry, primarily focusing on children's apparel and accessories. Founded in 1969, the company has established itself as a significant player in the sector, providing a variety of products including casual wear, dressy apparel, and footwear for children from newborn to pre-teens. Over the years, The Children's Place has embraced a multichannel retail strategy, incorporating both physical stores and a strong online presence. The company's commitment to digital transformation is evident through substantial investments in enhancing online platforms and implementing an integrated omni-channel operational model. This strategy focuses heavily on optimizing inventory management and customer engagement through technological advancements. |
Family Clothing Stores | 117.55 | 1.34 |
| 267 |
|
NAK / Northern Dynasty Minerals Ltd.
Northern Dynasty Minerals Ltd., based in Vancouver, Canada, is a mining company primarily engaged in the exploration and development of mineral properties. The company's signature venture is the Pebble Project, located in the Bristol Bay region of Alaska, USA. This project, one of the largest undeveloped copper and gold deposits in the world, has been a focal point of environmental scrutiny and regulatory challenges due to its potential impact on the region's significant salmon ecosystem. Despite these hurdles, Northern Dynasty Minerals continues to pursue the development of the Pebble Project, aiming to balance substantial economic benefits against environmental and cultural concerns, embodying its complex role in the mining industry. |
Gold And Silver Mining | 457.67 | 1.34 |
| 268 |
|
IRS / IRSA Inversiones y Representaciones Sociedad Anónima - Depositary Receipt (Common Stock)
IRSA Inversiones y Representaciones Sociedad Anónima, based in Argentina, primarily operates within the real estate sector. The company has established a prominent presence in various facets of the industry including shopping mall development, office buildings, and luxury hotels across significant urban markets in Argentina. Key projects include the development and management of major commercial shopping centers, such as the Alto Palermo and Abasto malls in Buenos Aires, and involvement in upscale residential developments. Likewise, IRSA has diversified its investment portfolio by venturing into agricultural land development and production, further highlighting its comprehensive approach to real estate and investment in Argentina's dynamic market environments. |
Land Subdividers and Developers, Except Cemeteries | 1.34 | |
| 269 |
|
RR / Richtech Robotics Inc. | General Industrial Machinery and Equipment, Not Elsewhere | 352.22 | 1.34 |
| 270 |
|
NSPR / InspireMD, Inc.
InspireMD, Inc., headquartered in Tel Aviv, Israel, operates primarily in the medical device industry. The company specializes in developing and commercializing proprietary MicroNet stent platform technology, specifically designed for vascular and coronary disease prevention. A notable project is their CGuard Carotid Embolic Prevention System, designed to prevent stroke by trapping potential emboli. Additionally, the firm works on improving its MGuard Prime EPS, which is employed in cardiac procedures to prevent embolic showers associated with stenting. These innovative projects underscore InspireMD's commitment to enhancing patient outcomes in complex cardiovascular and neurovascular interventions, focusing on achieving global regulatory approvals to expand its market reach. |
Surgical and Medical Instruments and Apparatus | 78.78 | 1.33 |
| 271 |
|
CDZI / Cadiz Inc.
Cadiz Inc. is an American land and water resource development company headquartered in Los Angeles, California. Positioned primarily in the environmental and water supply industries, the company's flagship project involves the storage and supply of water in California's Mojave Desert region. Notoriously known as the Cadiz Water Project, this initiative aims to capture and conserve billions of gallons of groundwater that would otherwise evaporate, providing a sustainable water source for Southern California’s communities and agricultural businesses. Additionally, Cadiz Inc. explores and has developed other resource management ventures that align with sustainable practice models, addressing the critical needs in regions with constrained water supplies. The company's strategic projects continue to stir public, regulatory, and scientific dialogue given their significant environmental implications and contributions to state water resource management. |
Water Supply | 290.73 | 1.33 |
| 272 |
|
TNGX / Tango Therapeutics, Inc. | Pharmaceutical Preparations | 770.56 | 1.33 |
| 273 |
|
BZUN / Baozun Inc. - Depositary Receipt (Common Stock)
Baozun Inc., based in China, operates primarily within the e-commerce industry, serving as a leading solutions provider for brands aiming to establish and expand their online presence in the Chinese market. The company offers end-to-end services including IT solutions, store operations, digital marketing, customer services, warehousing, and fulfillment. A key project for Baozun is its omnichannel commerce solution, which integrates both online and offline consumer experiences, tailoring e-commerce solutions that drive growth across diverse digital platforms. This strategic approach not only optimizes brand performance but also enhances user engagement through advanced technology and data analytics platforms, supporting Baozun's position as a vital partner for brands navigating the complexities of the Chinese e-commerce landscape. |
Catalog and Mail-Order Houses | 1.33 | |
| 274 |
|
AVIR / Atea Pharmaceuticals, Inc. | Pharmaceutical Preparations | 272.62 | 1.32 |
| 275 |
|
ADV / Advantage Solutions Inc.
Advantage Solutions Inc., based in the United States, operates primarily in the outsourced sales and marketing industry, focusing largely on consumer goods and retail services. The company provides a comprehensive suite of innovative solutions to enhance the execution of marketing and merchandising initiatives for its clients. Key projects often involve data-driven strategies that integrate analytics to improve product launches, promotional activities, and supply chain efficiencies for major consumer brands. A significant part of its offerings includes technology-enabled services that streamline operations and drive ROI for stakeholders across various consumer sectors. Additionally, Advantage Solutions specializes in tailored marketing programs that help manufacturers and retailers optimize market reach and consumer engagement. |
Business Services, Not Elsewhere Classified | 575.54 | 1.32 |
| 276 |
|
III / Information Services Group, Inc.
Information Services Group, Inc., based in the United States, is a leading global technology research and advisory firm. Operating in the information technology services industry, the company specializes in digital transformation services, including expertise in automation, cloud-based services, and data analytics. ISG provides strategic guidance, operational advice, and implementation support to both public and private sector organizations, aiding them in maximizing efficiency and achieving competitive advantages within their markets. One of their key projects includes offering managed governance and risk services designed to optimize IT investment outcomes. The firm often collaborates with businesses to restructure their IT operations, enhance technological capabilities, and navigate complex digital transitions, positioning themselves as essential partners in enterprise growth and innovation. |
Management Consulting Services | 253.44 | 1.31 |
| 277 |
|
FTHM / Fathom Holdings Inc. | Real Estate Agents and Managers | 55.52 | 1.31 |
| 278 |
|
GHRS / GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. GH Research PLC's initial focus is on developing its novel and proprietary 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression. |
Pharmaceutical Preparations | 870.27 | 1.30 |
| 279 |
|
SQNS / Sequans Communications S.A. - Depositary Receipt (Common Stock)
Sequans Communications S.A., based in Paris, France, is a notable player in the semiconductor industry, specializing in the design, development, and supply of cellular chipset solutions for massive, broadband, and critical IoT applications. The company's products are pivotal in facilitating efficient wireless broadband access, particularly for Internet of Things (IoT) devices across a spectrum of markets including telecommunications, networking, and automotive industries. Sequans has leveraged its technical expertise to develop a range of 5G and 4G chips, with projects that include Monarch 2 for LTE-M and NB-IoT applications, and Cascode for broadband high performance 5G devices. Through strategic partnerships and continuous innovation, Sequans remains at the forefront of facilitating advanced connectivity solutions for increasingly interconnected technology ecosystems. |
Semiconductors and Related Devices | 21.92 | 1.30 |
| 280 |
|
SATL / Satellogic Inc. | 368.36 | 1.30 | |
| 281 |
|
OABI / OmniAb, Inc. | Commercial Physical and Biological Research | 211.05 | 1.30 |
| 282 |
|
KOD / Kodiak Sciences Inc.
Kodiak Sciences Inc., based in the United States, operates primarily within the biotechnology industry, focusing on innovative therapeutics for treating chronic, high-prevalence retinal diseases. A key aspect of its project portfolio includes the development of the ABC Platform, designed to enhance the efficacy and durability of biologic therapies for retinal diseases. Notably, Kodiak Sciences is advancing KSI-301, a novel antibody biopolymer conjugate, through pivotal studies as a potential treatment for conditions such as wet age-related macular degeneration and diabetic eye diseases. This strategic focus underscores the company's commitment to addressing significant unmet medical needs in the ophthalmology sector, leveraging advanced science to improve patient outcomes. |
Biological Products, Except Diagnostic Substances (Biotech) | 555.76 | 1.30 |
| 283 |
|
DOMH / Dominari Holdings Inc.
Dominari Holdings Inc. is a diversified investment company based in the United States. The company operates primarily in the financial services industry, focusing on wealth management, merchant banking, and strategic investment initiatives. One of its key projects involves deploying innovative financial products designed to solve complex liquidity issues among emerging enterprises. Additionally, Dominari Holdings Inc. is actively engaged in developing proprietary hedge fund strategies that diversify and minimize risk for investors. The company has gained recognition for its holistic investment philosophy and has been involved in several strategic acquisitions, aligning itself with growth sectors such as technology and clean energy, which further enable it to extend its market influence and value creation capacities. |
Security Brokers, Dealers, and Flotation Companies | 88.98 | 1.29 |
| 284 |
|
ADSE / ADS-TEC Energy PLC
ADS-TEC Energy PLC is a Germany-based company that operates primarily in the energy sector with a focus on developing and manufacturing battery-based energy storage solutions. The company specializes in offering technology that supports the integration of renewable energy sources into existing grid infrastructures, enhancing efficiency and stability. Key projects include various battery storage systems and fast-charging solutions for electric vehicles that are designed to mitigate the impact of charging on the power grid. ADS-TEC Energy is noteworthy for its significant contributions to the advancement of energy storage technologies, which play a crucial role in the transition towards sustainable and decentralized energy systems. The company's offerings cater to a range of applications including industrial, commercial, and mobility solutions. |
Miscellaneous Transportation Equipment | 1.29 | |
| 285 |
|
PSNY / Polestar Automotive Holding UK PLC - Depositary Receipt (Common Stock)
Polestar Automotive Holding UK PLC, headquartered in the United Kingdom, operates prominently within the automotive industry, focusing chiefly on electric vehicles (EVs). As a progressive manufacturer, Polestar is distinguished by its commitment to innovation and sustainability, aiming to improve environmental impact through cutting-edge technologies in electric mobility. Key projects include its lineup of high-performance electric cars, such as the Polestar 1 and Polestar 2 models, which showcase advancements in EV technology and design. The company actively explores developments in battery technology and autonomous driving features, enhancing its competitiveness in the global market for luxury electric vehicles. Polestar's strategic initiatives emphasize both performance and eco-friendly automotive solutions, positioning it as a leader in the transition towards more sustainable transportation. |
Blank Check | 2,119.29 | 1.29 |
| 286 |
|
NRGV / Energy Vault Holdings, Inc. | Miscellaneous Electrical Machinery, Equipment, and Supplies | 331.02 | 1.29 |
| 287 |
|
CBLL / CeriBell, Inc. | 431.51 | 1.29 | |
| 288 |
|
FLL / Full House Resorts, Inc.
Full House Resorts, Inc., based in the United States, operates within the gaming industry, predominantly focusing on regional casino properties. The company is vested in the development and management of gaming facilities that include casinos, related hotel and entertainment facilities across multiple states. Key projects under its portfolio include the Silver Slipper Casino and Hotel in Mississippi, Bronco Billy's Casino and Hotel in Colorado, Rising Star Casino Resort in Indiana, and Stockman’s Casino in Nevada. Additionally, Full House is at the forefront of launching The Temporary by American Place in Waukegan, Illinois, marking a significant expansion move that anticipates an increase in visitor influx and revenue. These projects underscore the company's strategic initiative to tap into diverse regional markets, strengthening its market presence in the U.S. gaming sector. |
Hotels and Motels | 122.95 | 1.29 |
| 289 |
|
UPXI / Upexi, Inc. | Finance Services | 8.64 | 1.29 |
| 290 |
|
SYPR / Sypris Solutions, Inc. | Industrial Instruments for Measurement, Display, and Control of Process Variables; and Related Products | 48.36 | 1.29 |
| 291 |
|
XGN / Exagen Inc.
Exagen Inc. is a healthcare company based in the United States, specifically incorporated in Delaware and operationally headquartered in San Diego, California. Operating primarily within the biotechnology industry, Exagen is chiefly dedicated to developing and commercializing transformative diagnostic and healthcare solutions for autoimmune diseases. The company is particularly renowned for its Avise® diagnostic tests, which utilize proprietary biomarkers and algorithms to differentiate, prognose, and monitor autoimmune conditions, such as lupus and rheumatoid arthritis. By focusing on precision medicine, Exagen aims to improve patient outcomes and reduce healthcare costs through early and accurate disease detection and targeted therapy selections. This strategic approach leverages cutting-edge science to meet critical needs within the autoimmune disease community. |
Medical Laboratories | 213.17 | 1.29 |
| 292 |
|
GALT / Galectin Therapeutics Inc.
Galectin Therapeutics Inc., based in the United States, is a biotechnology firm focused on the development of therapies that target galectin proteins to treat fibrotic and other diseases. The company's lead project involves a proprietary compound, GR-MD-02, which is designed to inhibit galectin-3, a protein implicated in fibrosis (tissue scarring) and cancer. Galectin Therapeutics Inc. is actively involved in various clinical trials, primarily focusing on treatments for conditions such as non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis. Moreover, the company is exploring the therapeutic potential of its galectin inhibitors in other diseases characterized by severe fibrosis. In its endeavors, Galectin Therapeutics works towards developing novel therapeutic interventions that could provide significant clinical benefits in areas currently lacking effective treatments. |
Pharmaceutical Preparations | 294.23 | 1.29 |
| 293 |
|
WRAP / Wrap Technologies, Inc. | Ordnance And Accessories, Except Vehicles And Guided Missiles | 86.24 | 1.29 |
| 294 |
|
MIST / Milestone Pharmaceuticals Inc. | Pharmaceutical Preparations | 119.20 | 1.29 |
| 295 |
|
LWLG / Lightwave Logic, Inc. | Miscellaneous Plastics Products | 412.28 | 1.28 |
| 296 |
|
CTXR / Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc., based in the United States, operates primarily in the biopharmaceutical industry, focusing on developing and commercializing critical care products with a strong emphasis on anti-infectives, cancer care, and unique prescription products. Notably, Citius is advancing a diversified pipeline of products, including Mino-Lok®, an antibiotic lock solution aimed at treating patients with catheter-related bloodstream infections. Another significant project is Halo-Lido, formulated to provide symptomatic relief for hemorrhoids. These initiatives reflect the company's strategic focus on innovative therapies that address significant unmet medical needs in specialized areas of treatment, positioning Citius Pharmaceuticals as a noteworthy player in the development of advanced patient care solutions. |
Pharmaceutical Preparations | 17.80 | 1.28 |
| 297 |
|
MTSR / Metsera, Inc. | 3,758.31 | 1.28 | |
| 298 |
|
LXRX / Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., headquartered in the United States, operates within the biotechnology sector, primarily focused on the development and commercialization of breakthrough treatments for human disease. The company has concentrated its efforts on diabetes and cardiovascular diseases, among other serious health conditions. A key project includes their development of sotagliflozin, a drug designed to treat diabetes by improving glycemic control without necessitating insulin. The company leverages its unique bioinformatics and genetics understanding to pioneer these medications, aiming to meet significant unmet medical needs in the chronic disease sphere. Lexicon Pharmaceuticals has built a robust pipeline of drug candidates that are in various stages of clinical development, reinforcing its commitment to innovation in therapeutic healthcare solutions. |
Pharmaceutical Preparations | 399.74 | 1.28 |
| 299 |
|
BTCS / BTCS Inc.
BTCS Inc. is a U.S.-based company situated within the burgeoning blockchain technology sector. Primarily, it focuses on digital asset ecosystems and related technologies. A key player in the validation of transactions on blockchain networks, BTSC Inc. specializes in crypto staking on various blockchain infrastructure projects. This operation not only supports the underlying blockchain technology but also allows the company to generate revenue through rewards derived from the staking processes. Incredible growth potential rests on BTCS’s ability to expand its staking operations and investments in supportive technology for the blockchain space, which in turn augments its operational footprint and market influence in a rapidly evolving industry. |
Finance Services | 92.60 | 1.27 |
| 300 |
|
NGNE / Neurogene Inc. | Pharmaceutical Preparations | 284.67 | 1.27 |
| 301 |
|
TWIN / Twin Disc, Incorporated | General Industrial Machinery And Equipment | 183.96 | 1.27 |
| 302 |
|
PROF / Profound Medical Corp. | Surgical and Medical Instruments and Apparatus | 124.12 | 1.27 |
| 303 |
|
CHGG / Chegg, Inc.
Chegg, Inc., based in the United States, operates primarily in the education technology industry. Established to provide online textbook rentals, the company has significantly expanded its range of offerings. Chegg now provides a comprehensive suite of services designed to support students, including homework help, online tutoring, and test preparation platforms. Key projects arguably revolve around its digital subscription services, like Chegg Study and Chegg Tutor, which leverage advanced technology tools to offer tailored learning solutions. The company strategically integrates adaptive learning technologies to enhance educational accessibility and effectiveness, reflecting its commitment to breaking down barriers in the education sector and providing students with supportive learning environments. |
Educational Services | 184.37 | 1.27 |
| 304 |
|
ABAT / American Battery Technology Company | 213.03 | 1.27 | |
| 305 |
|
RILY / B. Riley Financial, Inc.
B. Riley Financial provides financial services solutions tailored to fit the capital raising, business, operational, and financial advisory needs of its clients and partners. B. Riley subsidiaries offer a range of capabilities spanning investment banking and institutional brokerage, private wealth and investment management, financial consulting, corporate restructuring, operations management, risk and compliance, due diligence, forensic accounting, litigation support, appraisal and valuation, auction and liquidation services. |
Investment Advice | 1.27 | |
| 306 |
|
SATS / EchoStar Corporation
EchoStar Corporation, based in the United States, is a prominent player in the global satellite communications sector. Specializing in satellite service operations, EchoStar provides satellite and video delivery solutions both within the U.S. and internationally. Key projects and services include broadband satellite technologies and services for home and office, satellite operations, and the provision of equipment necessary for satellite-based services. The company also focuses on offering Satellite Service solutions and manages a fleet of satellites through its Hughes Network Systems and EchoStar Satellite Services business segments. Through strategic initiatives, such as the expansion of its internet services and collaborations with other communication companies, EchoStar continues to enhance its comprehensive portfolio of satellite services, reinforcing its role as a major entity in the technology and communication industries. |
Communications Services, Not Elsewhere Classified | 10,514.18 | 1.27 |
| 307 |
|
CHRS / Coherus Oncology, Inc.
Coherus BioSciences, Inc., based in the United States, operates predominantly in the biotechnology industry, focusing on the development and commercialization of biosimilar therapies. The company aims to challenge the high cost of biologic medications in oncology and autoimmune diseases, offering more affordable patient access through reduced treatment expenses. Key projects include UDENYCA, a biosimilar to Neulasta, which aids in reducing the risk of infection during chemotherapy by boosting white blood cells. Furthermore, Coherus is involved in advancing a pipeline that includes biosimilars of leading drugs such as Humira and Avastin. These initiatives reflect its strategic focus on becoming a significant player in the biosimilar market, potentially transformative for both patient care and health economics. |
Biological Products, Except Diagnostic Substances (Biotech) | 150.51 | 1.26 |
| 308 |
|
BKKT / Bakkt Holdings, Inc. | Finance Services | 59.42 | 1.26 |
| 309 |
|
OM / Outset Medical, Inc. | Electromedical and Electrotherapeutic Apparatus | 248.90 | 1.26 |
| 310 |
|
MEIP / MEI Pharma, Inc.
MEI Pharma, Inc., based in the United States, specializes in the pharmaceutical industry with a strong focus on developing novel therapies for cancer treatment. The company's robust pipeline emphasizes oncology, where it is committed to advancing targeted therapeutics and bolstering its presence in this critical healthcare segment. Key projects include clinical-stage drug candidates such as Pracinostat, which is being developed as a treatment for various hematologic diseases and solid tumors. MEI Pharma has forged strategic partnerships to drive its research and development efforts, aiming to produce innovative, efficacious cancer treatments. This strategic approach allows MEI Pharma to not only expand its clinical reach but also enhances its potential market impact through advanced therapeutic options. |
Pharmaceutical Preparations | 28.28 | 1.26 |
| 311 |
|
NMRA / Neumora Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 272.88 | 1.26 |
| 312 |
|
BZFD / BuzzFeed, Inc. | Communications Services, Not Elsewhere Classified | 68.89 | 1.26 |
| 313 |
|
REPL / Replimune Group, Inc.
Replimune Group, Inc. is a biotechnology firm based in the United States, specializing primarily in the development of oncolytic immuno-gene therapies. The company aims to innovate cancer treatment through its proprietary platform that employs genetically modified viruses designed to selectively kill tumor cells, enhance the immune system's natural responses, and induce a robust, systemic anti-tumor response. One of its key projects includes the development of RP1, an investigational therapy which has entered clinical trials and shows potential in treating various types of cancers including melanoma, non-melanoma skin cancers, and bladder cancer. Replimune's focus on harnessing and improving the body's innate ability to fight cancer positions it as a notable entity in the oncology sector. |
Biological Products, Except Diagnostic Substances (Biotech) | 492.13 | 1.25 |
| 314 |
|
IMAB / I-Mab - Depositary Receipt (Common Stock)
I-Mab, based in China, operates as a clinical-stage biopharmaceutical company primarily involved in the discovery, development, and potential commercialization of innovative biologics in the therapeutic area of immuno-oncology and autoimmune diseases. As a player in the biotech industry, I-Mab stands out due to its robust pipeline that includes several late-stage assets and other drug candidates in various stages of clinical trials globally. Notably, the company is committed to addressing critical unmet medical needs by advancing a wave of novel therapies, focusing on bringing pioneering treatments to patients worldwide. The strategic deployment of its resources underscores its dedication to achieving milestones in biologic therapy innovations, exemplified by its continued progression to phase III clinical trials in some candidate drugs. |
Pharmaceutical Preparations | 360.27 | 1.25 |
| 315 |
|
BLND / Blend Labs, Inc. | Computer Programming, Data Processing, And Other Computer Related Services | 1,048.01 | 1.25 |
| 316 |
|
STIM / Neuronetics, Inc.
Neuronetics, Inc., based in the United States, operates primarily within the medical device industry, focusing on pioneering treatments for psychiatric disorders. A notable project of Neuronetics is the development of its proprietary NeuroStar Advanced Therapy system, a non-invasive treatment that utilizes transcranial magnetic stimulation (TMS) technology to alleviate depression. Established with an intention to innovate solutions for mental health issues, the company notably addresses conditions that are often resistant to conventional treatments. Neuronetics’ role in advancing neuromodulation therapies positions it as a key player in the mental health sector, contributing to broader healthcare objectives by providing clinically significant improvements in patient outcomes through technology-driven treatments. |
Surgical and Medical Instruments and Apparatus | 213.21 | 1.25 |
| 317 |
|
PSNL / Personalis, Inc.
Personalis, Inc. is a genomics-based precision medicine company headquartered in the United States. Founded in 2011, the company primarily serves the biopharmaceutical industry with a focus on providing advanced genomic sequencing and analytics. Key to its operations is the Personalis NeXT Platform, designed to offer comprehensive molecular data of cancer tissues, which is crucial for the development of personalized cancer vaccines and other targeted therapies. Personalis extends its expertise beyond oncology, supporting population sequencing projects and clinical trials globally. By integrating innovative technology and extensive genomic intelligence, Personalis, Inc. plays a pivotal role in the advancement of precision medicine, striving to enhance personalized treatment approaches across various diseases. |
Medical Laboratories | 464.97 | 1.24 |
| 318 |
|
NPWR / NET Power Inc. | Electrical Industrial Apparatus | 170.56 | 1.24 |
| 319 |
|
ONDS / Ondas Holdings Inc.
Ondas Holdings Inc., based in the United States, operates primarily in the technology sector, focusing on wireless communications systems and solutions. The company specializes in developing proprietary, wide-area broadband networks designed to support industrial IoT applications through its subsidiary, Ondas Networks. These networks cater to vital industries such as utilities, transportation, and government services. Additionally, Ondas Holdings has expanded into the drone space with its acquisition of American Robotics, a company engaged in the development of fully-automated commercial drone systems. This strategic move diversifies Ondas' portfolio into autonomous aerial technology, aiming to enhance operational efficiencies and data collection capabilities across various sectors. Through these initiatives, Ondas Holdings is positioning itself as a leader in scalable, high-performance wireless communications and autonomous drone technology. |
Radio and Television Broadcasting and Communications Equipment | 1,165.97 | 1.23 |
| 320 |
|
CMPX / Compass Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 476.38 | 1.23 |
| 321 |
|
RNAC / Cartesian Therapeutics, Inc.
Cartesian Therapeutics, Inc., based in the United States, operates primarily in the biotechnology sector, focusing on the development of innovative therapeutics. The company stands out for its pioneering work in engineered cell therapies targeting autoimmune diseases, cancer, and respiratory conditions. A significant aspect of Cartesian Therapeutics' approach involves utilizing mRNA technology to modify cells, aiming for more controlled and robust treatment responses. Among its key projects are targeted therapies for myasthenia gravis and acute respiratory distress syndrome, reflecting its commitment to addressing complex medical challenges. The firm leverages cutting-edge scientific methodologies to advance its pipeline, demonstrating a strong commitment to revolutionizing the treatment landscape through biotechnological breakthroughs. |
Pharmaceutical Preparations | 277.16 | 1.23 |
| 322 |
|
PLX / Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc., based in Israel, operates within the biopharmaceutical sector, focusing primarily on the development and commercialization of recombinant therapeutic proteins through its proprietary ProCellEx plant cell-based expression system. The company targets a range of complex diseases, including rare disorders. A prominent project of Protalix is Elelyso, an enzyme replacement therapy approved for Gaucher disease, developed in partnership with Pfizer. Another key initiative includes advancing treatments for Fabry disease and other conditions where traditional enzyme replacement therapies are employed. The company's novel technology and strategic partnerships underline its position as a pioneer in leveraging plant biotechnology for biopharmaceutical applications, aligning its product pipeline directly with significant, unmet medical needs. |
Biological Products, Except Diagnostic Substances (Biotech) | 123.19 | 1.23 |
| 323 |
|
TELA / TELA Bio, Inc. | Surgical and Medical Instruments and Apparatus | 63.33 | 1.22 |
| 324 |
|
CTOS / Custom Truck One Source, Inc. | Equipment Rental and Leasing, Not Elsewhere Classified | 1,379.75 | 1.22 |
| 325 |
|
VFS / VinFast Auto Ltd. | 7,823.33 | 1.22 | |
| 326 |
|
FFAI / Faraday Future Intelligent Electric Inc.
Faraday Future Intelligent Electric Inc., based in the United States, operates within the automotive industry, specializing in the design and manufacture of electric vehicles (EVs). Integral to its development strategy is the promotion of cutting-edge proprietary technologies and software, aiming to revolutionize mobility solutions. One of its flagship projects includes the FF 91, a luxury electric SUV designed to compete directly with major players in the EV market by offering superior performance, innovative user-experience technologies, and autonomous driving capabilities. The company has focused on integrating unique features such as Internet, AI, and other advanced technological components, positioning itself as a frontrunner in the luxury EV segment and emphasizing sustainability and futuristic transportation solutions. |
Motor Vehicles and Passenger Car Bodies | 222.14 | 1.22 |
| 327 |
|
DBI / Designer Brands Inc.
Designer Brands Inc., headquartered in Columbus, Ohio, USA, is a prominent player in the footwear and accessories sector, operating as a designer, producer, and retailer. The company boasts an extensive portfolio of owned and licensed brands, catering to a diverse market through its vast network of retail stores and an assertive online presence. Pivotal to its strategic endeavors are the expansion of its Exclusive Brand offerings and significant advancements in digital transformation, which aim to enhance consumer engagement and operational efficiencies. Designer Brands' agility in adapting to changing market trends, coupled with its focus on innovative distribution and marketing strategies, underscores its commitment to maintaining a competitive edge in the dynamic retail landscape. |
Shoe Stores | 230.03 | 1.22 |
| 328 |
|
ATOS / Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc., based in the United States, is a clinical-stage biopharmaceutical company focused on developing innovative therapies in oncology and infectious diseases. Notably, the company has concentrated its efforts on breast cancer treatments and other significant unmet medical needs. A prominent project includes the development of Endoxifen, an oral formulation designed to reduce mammographic breast density and treat breast cancer. Additionally, Atossa is exploring novel therapeutic options for severe COVID-19, aiming to enhance the healthcare community's ability to combat this and potentially future pandemics. The company's strategic initiatives are geared towards advancing their proprietary therapeutics from concept through clinical development, with an emphasis on addressing critical treatment gaps in global health. |
Pharmaceutical Preparations | 101.81 | 1.21 |
| 329 |
|
PRQR / ProQR Therapeutics N.V.
ProQR Therapeutics N.V. is a biopharmaceutical company based in the Netherlands, primarily focused on developing transformative RNA therapies for severe genetic rare diseases. ProQR leverages its proprietary technology platforms to enhance RNA molecules for specific therapeutic targeting. A notable project includes their lead compound, sepofarsen, designed for the treatment of Leber’s congenital amaurosis, an inherited form of blindness. Additionally, the company is advancing a broad pipeline that includes potential treatments for cystic fibrosis and dystrophic epidermolysis bullosa. ProQR’s strategic approach combines rigorous scientific research with a commitment to addressing unmet medical needs in the area of genetic disorders, aiming to offer innovative solutions that significantly improve patient care. |
Pharmaceutical Preparations | 260.20 | 1.21 |
| 330 |
|
VUZI / Vuzix Corporation | Radio and Television Broadcasting and Communications Equipment | 187.17 | 1.21 |
| 331 |
|
CPSH / CPS Technologies Corporation | Pottery And Related Products | 49.38 | 1.21 |
| 332 |
|
ZBIO / Zenas BioPharma, Inc. | 863.24 | 1.21 | |
| 333 |
|
QNCX / Quince Therapeutics, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 86.87 | 1.21 |
| 334 |
|
TSHA / Taysha Gene Therapies, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 915.01 | 1.20 |
| 335 |
|
TGEN / Tecogen Inc.
Tecogen Inc. is an American company based in Waltham, Massachusetts, primarily engaged in the design, manufacture, sale, and maintenance of cogeneration products, including combined heat and power, air conditioning systems, and high-efficiency water heaters for residential, commercial, recreational, and industrial use. The company’s key projects typically focus on innovative clean energy solutions, emphasizing energy cost reduction and carbon footprint minimization for its clients. Tecogen's technology portfolio includes advanced ultra-low-emission control technologies integrated into their InVerde, TecoChill, and Ilios branded products. These installations are significant in light-sensitive environments such as hospitals, hotels, and educational institutions, demonstrating Tecogen's commitment to reliable and environmentally sustainable energy production. |
Air-Conditioning and Warm Air Heating Equipment and Commercial and Industrial Refrigeration Equipment | 181.05 | 1.20 |
| 336 |
|
SY / So-Young International Inc. - Depositary Receipt (Common Stock) | Computer Processing and Data Preparation and Processing Services | 372.45 | 1.19 |
| 337 |
|
ANRO / Alto Neuroscience, Inc. | Pharmaceutical Preparations | 99.63 | 1.19 |
| 338 |
|
MVIS / MicroVision, Inc.
MicroVision, Inc. is an American technology firm based in Redmond, Washington, primarily engaged in the development of laser scanning technology for projection, 3D sensing, and image capture. The company focuses on producing miniature laser display and sensing systems based on its proprietary PicoP® scanning technology, which integrates MEMS (Micro-Electrical Mechanical Systems), laser diodes, optics, and electronics to create compact, high-resolution displays and imaging systems. Key projects typically involve applications in automotive lidar sensors, augmented reality systems, and portable devices. MicroVision aims to innovate within the rapidly advancing field of optical electronics, contributing directly to sectors that demand precision, miniaturization, and enhanced functionality in imaging technology. |
Electronic Components, Not Elsewhere Classified | 283.94 | 1.19 |
| 339 |
|
STEM / Stem, Inc.
Stem, Inc., based in the United States, operates predominantly in the energy sector, focusing on smart energy storage solutions and software-driven technology. The company plays a pivotal role in the evolution of the renewable energy sector by providing advanced energy storage systems and a software analytics platform, known as Athena, to enhance energy efficiency and reliability. Stem’s projects predominately consist of deploying large-scale battery storage solutions and leveraging machine learning to optimize energy usage and cost reductions for businesses and grids. Key collaborations include partnerships with leading energy providers and technology firms to foster grid interactivity and incorporate renewable integration, exemplifying its commitment to transforming how energy is distributed and consumed globally. |
Miscellaneous Electrical Machinery, Equipment, and Supplies | 116.10 | 1.19 |
| 340 |
|
GPRK / GeoPark Limited
GeoPark Limited is an oil and gas exploration and production company based in Bermuda, primarily operating in Latin America. Active in the industry since 2002, the company's core activities center around the exploration, development, and production of oil and natural gas reserves. Key countries of operation include Colombia, Ecuador, Chile, Brazil, and Argentina. GeoPark has made significant strides in its project portfolio, with notable developments like the Llanos 34 block in Colombia, which has been a major contributor to its production growth. The company's strategic focus on sustainable and efficient operations has allowed it to establish a resilient and growing presence in the region's energy sector, navigating the complex challenges associated with hydrocarbon extraction and market fluctuations. |
Crude Petroleum and Natural Gas | 327.45 | 1.19 |
| 341 |
|
SANA / Sana Biotechnology, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 682.31 | 1.19 |
| 342 |
|
OPTT / Ocean Power Technologies, Inc.
Ocean Power Technologies, Inc., based in the United States, is a pioneering company within the renewable energy sector, specifically in the industry of wave energy conversion. The firm primarily focuses on designing and manufacturing innovative systems that harness ocean wave energy to generate reliable and environmentally friendly electricity. A key project of the company includes its flagship PB3 PowerBuoy system, which captures wave energy to power subsea equipment, sensor arrays, and remote oceanographic data collection. Ocean Power Technologies' offerings underscore a commitment to sustainable energy solutions and have applications across various sectors, including defense, oil and gas, and scientific research, broadening the practical utilization of renewable energy resources in tackling energy challenges globally. |
Electric Services | 85.51 | 1.19 |
| 343 |
|
DHC / Diversified Healthcare Trust
Diversified Healthcare Trust is a real estate investment trust based in the United States, specifically focused on owning and managing healthcare-related properties. Primarily operating within the healthcare sector, its portfolio comprises properties across various categories including medical office buildings, inpatient rehabilitation hospitals, and life science properties. The trust’s strategy is centered on leveraging the growing demand for healthcare infrastructure by acquiring, developing, and managing facilities in high-growth areas. Key projects include strategic redevelopments and enhancements aimed at boosting facility value and attractability to tenants, particularly in high-tech and high-potential markets. Diversified Healthcare Trust's investment approach underpins its mission to provide well-maintained and strategically located healthcare facilities that meet the evolving needs of its tenants and their patients. |
Real Estate Investment Trusts | 997.07 | 1.19 |
| 344 |
|
RAPT / RAPT Therapeutics, Inc.
RAPT Therapeutics, Inc., based in the United States, operates within the biotechnology industry, specializing in the discovery and development of oral small molecule therapies for patients suffering from systemic inflammatory diseases and cancer. The company leverages its proprietary discovery platform to target specific molecules that modulate the immune system, focusing notably on TH1 and TH17 driven diseases. Key projects at RAPT include the development of treatments such as FLX475, targeting T cell trafficking for various cancers, and RPT193, aimed at addressing inflammatory diseases like atopic dermatitis. This strategic focus on immune-driven conditions positions RAPT Therapeutics to potentially impact a significant patient demographic across multiple disease areas. |
Pharmaceutical Preparations | 217.95 | 1.19 |
| 345 |
|
IRBT / iRobot Corporation
iRobot Corporation, based in the United States, operates within the consumer electronics industry and specializes in the design and manufacturing of robots for both domestic and military use. Renowned for its Roomba vacuum cleaning robots, the company has significantly influenced home automation through the development of autonomous technology geared towards easing everyday domestic tasks. Beyond consumer products, iRobot has engaged in several key projects within the defense sector, creating robotic technology designed for reconnaissance and bomb disposal. This dual approach—serving both everyday consumers and government contracts—underscores iRobot's strategic positioning within the evolving field of robotics, constantly innovating to expand its product range and market presence while enhancing operational efficiency through automation. |
Household Appliances | 101.44 | 1.18 |
| 346 |
|
CMTG / Claros Mortgage Trust, Inc.
Claros Mortgage Trust, Inc., based in the United States, operates primarily within the real estate sector, focusing on commercial real estate mortgage loans. As a real estate investment trust (REIT), its portfolio includes a diverse range of loan assets including bridge and mezzanine loans, which are instrumental for clients managing transitional properties. The trust strategically issues these loans against commercial properties that are under redevelopment or repositioning, targeting loans typically secured by properties in transition with value-added elements. A significant component of Claros Mortgage Trust's activities involves meticulous analysis and selection of commercial mortgage opportunities that demonstrate potential for high yields and growth, aligning with its investment strategy to maximize returns for shareholders while managing risk effectively. |
Real Estate | 537.62 | 1.18 |
| 347 |
|
PRME / Prime Medicine, Inc. | National Commercial Banks | 486.75 | 1.18 |
| 348 |
|
MGNX / MacroGenics, Inc.
MacroGenics, Inc. is a biopharmaceutical company headquartered in the United States. It primarily focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and other severe diseases. MacroGenics leverages its proprietary technology platforms, such as DART® and TRIDENT™, to create antibody-based drugs aimed at improving patient outcomes in diseases that currently have limited treatment options. A key project includes the development of margetuximab, an anti-HER2 antibody recently approved by the FDA for breast cancer under the name Margenza. Additionally, MacroGenics has a robust pipeline of candidates in various stages of clinical development targeting a range of oncological and autoimmune diseases. The company demonstrates a strong commitment to advancing science and medicine to meet unmet medical needs. |
Pharmaceutical Preparations | 126.41 | 1.18 |
| 349 |
|
CMTL / Comtech Telecommunications Corp.
Comtech Telecommunications Corp., based in the United States, operates predominantly within the global communications sector. The company specializes in providing advanced communication solutions, including command and control technologies, safety and security technologies, and location and messaging services. Comtech's significant projects focus on developing and enhancing satellite ground station technologies and high-performance transmission capabilities. Its services are pivotal for defense, public safety, and commercial applications, enabling reliable and secure communication necessary for operations in remote and challenging environments. The company's strategic direction emphasizes innovation in communications technology to maintain and expand its footprint in these critical areas, supported by ongoing research and development initiatives. |
Radio and Television Broadcasting and Communications Equipment | 64.89 | 1.18 |
| 350 |
|
DEFT / DeFi Technologies Inc.
DeFi Technologies Inc., based in Canada, operates within the burgeoning decentralized finance (DeFi) sector, an industry focused on recreating and innovating upon traditional financial services through blockchain technology. The company primarily engages in developmental support, investment, and management of DeFi assets, notably by constructing and nurturing protocols and services that aim to democratize finance by minimizing reliance on central financial intermediaries. Key projects under DeFi Technologies include initiatives around yield farming, liquidity provision, and trading services on decentralized exchanges (DEXs). Additionally, through strategic partnerships and proprietary platforms, the company is at the frontline of offering exposure to DeFi and related assets, enhancing access and engagement for mainstream investors with this disruptive financial technology. |
678.62 | 1.18 | |
| 351 |
|
RZLV / Rezolve AI PLC | 1.17 | ||
| 352 |
|
DFDV / DeFi Development Corp. | Commodity Contracts Brokers and Dealers | 260.69 | 1.17 |
| 353 |
|
GAIA / Gaia, Inc.
Gaia, Inc. is a United States-based company focusing primarily on the provision of subscription video streaming services, predominantly delivering original content. Positioned in the entertainment and media sector, Gaia operates from its headquarters in Louisville, Colorado. The company specializes in curated programming that appeals to a niche audience interested in conscious media, emphasizing themes such as spirituality, holistic health, and personal development. Gaia's strategic initiatives revolve around expanding its subscriber base, enhancing content offerings, and boosting engagement through platforms that facilitate user interaction and connectivity. By continuously evolving its content library with unique, self-produced titles and series, Gaia aims to distinguish itself within the competitive landscape of digital media and subscription services. |
Motion Picture, Film, and Video Tape Production | 139.22 | 1.17 |
| 354 |
|
SPRO / Spero Therapeutics, Inc.
Spero Therapeutics, Inc., based in the United States, operates within the biopharmaceutical sector, focusing primarily on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections. A key flagship project of Spero Therapeutics is its innovative product, Tebipenem HBr, which is an orally administered carbapenem antibiotic currently in advanced clinical trials aimed at treating complicated urinary tract infections (cUTI) caused by certain antibiotic-resistant pathogens. This approach marks a significant advancement in addressing critical public health threats posed by antibiotic resistance. Spero's pipeline also includes other novel therapies that target the underlying mechanisms of bacterial resistance, showcasing their commitment to combating infectious diseases through breakthrough scientific innovations. |
Pharmaceutical Preparations | 121.08 | 1.17 |
| 355 |
|
ORGN / Origin Materials, Inc.
Origin Materials, Inc., headquartered in the United States, is a pioneering chemical company dedicated to developing innovative carbon-negative materials that can replace petroleum-based products. This enterprise operates primarily within the renewable materials sector, focusing on technology that utilizes non-food biomass as a feedstock to produce intermediate and end-use chemicals. Its key projects include partnerships with major corporations seeking to reduce their carbon footprints using Origin's patented technology platform. Noteworthy collaborations include those with Nestlé and Danone, aimed at producing sustainable plastics for various applications. Origin Materials' business approach combines advancing environmental sustainability with meeting the growing demand for green consumer products, positioning itself strongly in the emerging bio-based economy. |
Industrial Organic Chemicals | 75.90 | 1.17 |
| 356 |
|
LTRX / Lantronix, Inc. | Computer Communications Equipment | 184.96 | 1.17 |
| 357 |
|
PLSE / Pulse Biosciences, Inc.
Pulse Biosciences, Inc. is a U.S.-based company operating within the biomedical sector, specifically focused on developing therapeutic technologies utilizing its proprietary Nano-Pulse Stimulation (NPS) platform. The company is headquartered in Hayward, California, and specializes in designing and marketing devices that apply ultra-short but intense electrical pulses to cells, aiming to induce beneficial cellular responses in medical and aesthetic applications. Key projects include the development of its CellFX System, a device designed for dermatological procedures to precisely target cellular structures without affecting surrounding non-cellular tissue. The technology holds the potential for applications across various medical fields, including oncology, dermatology, and immunotherapy, signaling innovative growth avenues in tissue and cell-based medical therapies. |
Surgical and Medical Instruments and Apparatus | 1,014.55 | 1.16 |
| 358 |
|
AGL / agilon health, inc. | Miscellaneous Health And Allied Services, Not | 495.07 | 1.16 |
| 359 |
|
VERI / Veritone, Inc. | Computer Processing and Data Preparation and Processing Services | 126.33 | 1.16 |
| 360 |
|
SYRE / Spyre Therapeutics, Inc.
Aeglea BioTherapeutics Inc. is a U.S.-based biotechnology company focused on developing enzyme-based therapeutics in the field of amino acid metabolism. |
Pharmaceutical Preparations | 1,025.13 | 1.16 |
| 361 |
|
VOR / Vor Biopharma Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 245.64 | 1.16 |
| 362 |
|
ADVM / Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc., based in the United States, operates within the biotechnology industry, focusing on the development of gene therapy products. The company's primary project revolves around innovative therapies for ocular and rare diseases, using its proprietary vector platforms to address conditions like age-related macular degeneration. Adverum is pioneering in the area of adeno-associated virus (AAV) vectors, a technology that facilitates the delivery of genetic material into cells. Their lead product candidate, ADVM-022, is an investigational gene therapy designed for the treatment of wet age-related macular degeneration, representing a significant advancement in the field and demonstrating their commitment to addressing unmet medical needs through gene therapy solutions. |
Biological Products, Except Diagnostic Substances (Biotech) | 74.28 | 1.16 |
| 363 |
|
GPRO / GoPro, Inc.
GoPro, Inc., based in the United States, operates primarily within the consumer electronics sector, focusing on the design and manufacture of action cameras, mobile apps, and video-editing software. Renowned for its robust and portable camera systems, GoPro has carved out a niche in capturing extreme action video footage, appealing to sports enthusiasts and adventurers. Its flagship product line includes the HERO series, which has evolved through several iterations to include features such as 4K video recording, cloud connectivity, and stabilization technologies. GoPro has also expanded its project portfolio to include software solutions like the Quik app, designed to facilitate video editing and sharing, thereby reinforcing its ecosystem and enhancing user engagement. |
Photographic Equipment and Supplies | 236.97 | 1.16 |
| 364 |
|
INNV / InnovAge Holding Corp. | Pharmaceutical Preparations | 511.95 | 1.16 |
| 365 |
|
TTSH / Tile Shop Holdings, Inc. | Home Furniture, Furnishings, And Equipment Stores | 278.08 | 1.16 |
| 366 |
|
EDIT / Editas Medicine, Inc.
Editas Medicine, Inc., based in the United States, operates within the biotechnology sector and is notable for its pioneering efforts in gene editing technology. Specializing in the CRISPR/Cas9 and CRISPR/Cas12 systems, the company focuses on developing transformative gene-editing therapies to treat a diverse range of diseases with unmet medical needs. Key projects include a leading development program targeting Leber Congenital Amaurosis type 10 (LCA10), a severe genetic eye disorder, endeavoring to correct this mutation-driven ailment at the DNA level. Additionally, Editas Medicine sustains active research in exploring treatment options for other genetic conditions, including sickle cell disease and beta-thalassemia, signifying its strategic commitment to medical innovation and genetic disease treatment. |
Biological Products, Except Diagnostic Substances (Biotech) | 240.76 | 1.16 |
| 367 |
|
PROK / ProKidney Corp. | Biological Products, Except Diagnostic Substances (Biotech) | 300.86 | 1.15 |
| 368 |
|
NB / NioCorp Developments Ltd.
NioCorp Developments Ltd. is a mining corporation headquartered in Centennial, Colorado, USA. It primarily focuses on extracting and developing critical minerals necessary for various advanced industries, such as green energy and technology sectors. Its flagship project is the Elk Creek Superalloy Materials Project located in Nebraska. This project is significant due to its rich deposits of niobium, scandium, and titanium, which are essential for producing superalloys and other high-performance materials. As of the most recent updates, NioCorp is working towards securing financing and obtaining necessary permits to advance the project towards the construction and operational phases, positioning itself strategically within the critical minerals market essential for modern technologies. |
Metal Mining | 201.26 | 1.15 |
| 369 |
|
MAPS / WM Technology, Inc. | Prepackaged Software | 125.99 | 1.15 |
| 370 |
|
EHTH / eHealth, Inc.
EHealth, Inc., based in the United States, primarily operates within the health insurance sector. This company has carved out a niche in the digital healthcare space by providing a comprehensive online platform for insurance information and comparison. Its primary product is an Internet-based portal where consumers can compare health insurance plans from multiple providers to find the coverage that best suits their needs. EHealth, Inc. also offers a range of tools and services, such as enrollment in Medicare, individual, and family insurance plans directly through their platform. Their initiatives aim to simplify the insurance selection process by leveraging technology to enhance accessibility and consumer choice in health insurance markets. |
Insurance Agents, Brokers, and Service | 124.20 | 1.15 |
| 371 |
|
ATAI / Atai Life Sciences N.V.
Atai Life Sciences N.V., headquartered in the Netherlands, operates primarily within the biotechnology sector, specializing in the development of treatments for mental health disorders. The company employs a unique approach by focusing on psychedelic and non-psychedelic compounds to innovate solutions for conditions that are typically resistant to conventional therapies. A key pillar of Atai Life Sciences' work revolves around leveraging advanced scientific research to demystify and effectively target the underlying biological mechanisms of mental illnesses. Central to their mission, Atai invests in a diverse portfolio of therapeutic projects that explore novel drug development pathways, including the exploration of psilocybin and other compounds, to address significant unmet medical needs in the psychiatric space, aiming at revolutionizing the mental health treatment landscape. |
Pharmaceutical Preparations | 968.90 | 1.15 |
| 372 |
|
ETHZ / ETHZilla Corporation
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. |
Pharmaceutical Preparations | 14.01 | 1.15 |
| 373 |
|
ARBE / Arbe Robotics Ltd. | Blank Check | 145.29 | 1.14 |
| 374 |
|
GTE / Gran Tierra Energy Inc.
Gran Tierra Energy Inc., headquartered in Calgary, Canada, operates as an international oil and gas exploration and production company, primarily focused on opportunities in South America. With a strong presence in Colombia, where the majority of its operations and key assets are located, the company is involved in the development of both conventional and unconventional reservoirs. Gran Tierra holds a strategic portfolio of assets that includes significant acreage in the Putumayo and Middle Magdalena Valleys, which are known for their substantial hydrocarbon potential. The company's approach combines a commitment to operational excellence and sustainable practices, aiming to leverage technological expertise and in-depth regional knowledge to optimize asset performance and production efficiency. |
Crude Petroleum and Natural Gas | 138.51 | 1.14 |
| 375 |
|
AXTI / AXT, Inc.
AXT, Inc. is a U.S.-based company, headquartered in Fremont, California, that specializes in the production of semiconductor substrates. The company operates principally within the semiconductor industry, focusing on the manufacture of high-performance, compound semiconductor substrates which include materials such as gallium arsenide, indium phosphide, and germanium. These materials are vital for applications in high-speed communication, wireless, and optoelectronic products. Key projects and activities routinely involve enhancing material development to aid advancements in electronic and optoelectronic device markets. The company maintains a global presence with significant manufacturing capabilities in China, serving both international and domestic markets, thus underpinning its strategic position in the semiconductor substrate sector. |
Semiconductors and Related Devices | 135.89 | 1.14 |
| 376 |
|
KOPN / Kopin Corporation
Kopin Corporation, based in the United States, is a prominent player in the microdisplay technology sector, focusing primarily on manufacturing high-resolution screens for a variety of military, consumer, and industrial applications. The company's diverse product lineup includes ultra-small displays for use in virtual and augmented reality (VR and AR), thermal weapon sights, and pilot helmets. Noteworthy projects include innovative partnerships with defense departments for enhancing the capabilities of military equipment through improved head-mounted displays. Kopin Corporation is also actively involved in evolving consumer electronics through the development of lightweight, power-efficient solutions for VR and AR glasses, positioning itself as a key contributor to the advancement of next-generation wearable technologies. |
Semiconductors and Related Devices | 331.97 | 1.14 |
| 377 |
|
PL / Planet Labs PBC | 1,987.29 | 1.14 | |
| 378 |
|
EVTL / Vertical Aerospace Ltd. | Aircraft | 387.82 | 1.13 |
| 379 |
|
RAVE / Rave Restaurant Group, Inc. | Groceries And Related Products | 48.60 | 1.13 |
| 380 |
|
DLNG / Dynagas LNG Partners LP - Limited Partnership
Dynagas LNG Partners LP, based in Greece, operates within the energy sector, primarily focusing on the transportation of liquefied natural gas (LNG) through its fleet of LNG carriers. This limited partnership specializes in the ownership and management of LNG vessels engaged in multi-year charters, aligning with major energy companies and users. Its fleet consists of specifically designed LNG carriers that cater to different geographical, technical, and contractual needs. Key projects typically involve long-term charters which provide steady and predictable revenue streams, crucial for maintaining and expanding its operational capabilities. Dynagas has positioned itself strategically within the LNG transportation industry, optimizing its fleet utilization and financial performance through long-standing industry relationships and technical expertise in marine logistics. |
Water Transportation | 138.44 | 1.13 |
| 381 |
|
SIFY / Sify Technologies Limited - Depositary Receipt (Common Stock)
Sify Technologies Limited is an information and communications technology company based in India. It operates primarily in the provision of integrated ICT solutions and services, such as managed network, data center solutions, and software services across various industries. A key aspect of Sify's portfolio includes enhancing enterprise connectivity through offerings like internet, network, and cloud solutions. Additionally, the company has made significant investments in expanding its data center capabilities, aiming to establish a more robust infrastructure platform that supports a wide range of business operations and e-commerce solutions. Sify Technologies also drives projects that facilitate digital transformation for its clients, thereby reinforcing its position in the rapidly evolving ICT sector. |
Computer Programming, Data Processing, And Other Computer Related Services | 1.13 | |
| 382 |
|
SPWH / Sportsman's Warehouse Holdings, Inc.
Sportsman's Warehouse Holdings, Inc., headquartered in the United States, operates primarily in the retail industry focused on outdoor sporting goods. Specializing in a wide array of products, the company caters to outdoor enthusiasts, offering equipment, apparel, and accessories for hunting, fishing, camping, and shooting sports. Sportsman's Warehouse has grown significantly since its inception, leveraging both brick-and-mortar stores and an online platform to reach a broad consumer base. The company’s strategic initiatives often include expanding their physical store footprint and enhancing their e-commerce capabilities to better serve their customer base and compete effectively in the outdoor sporting goods market. Through these efforts, Sportsman's Warehouse continues to strengthen its market position by providing high-quality products and expertise in the outdoor sports industry. |
Miscellaneous Shopping Goods Stores | 130.03 | 1.13 |
| 383 |
|
HIVE / HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd., based in Canada, operates primarily within the cryptocurrency mining sector. It focuses on the mining of digital currencies like Bitcoin and Ethereum, utilizing green energy to power its operations, thereby addressing environmental concerns associated with crypto-mining. By harnessing renewable energy sources, HIVE aims to achieve a lower carbon footprint compared to conventional mining practices. In addition to its core mining activities, the company is also involved in the development of data center infrastructure essential for its mining operations. This strategic approach not only enhances its operational efficiency but also bolsters its capacity to scale in a rapidly evolving digital currency landscape. |
Finance Services | 542.48 | 1.12 |
| 384 |
|
AEHR / Aehr Test Systems, Inc.
Aehr Test Systems is a leading provider of semiconductor test equipment based in the United States, with its headquarters in Fremont, California. Operating primarily within the semiconductor industry, the company focuses on developing and manufacturing advanced systems for ensuring the reliability of semiconductor devices both during production and post-production phases. Key products include test fixtures, burn-in, and test systems that are essential for assessing the functionality and endurance of integrated circuits and silicon wafers. A prominent project is its FOX-XP system, which supports high volume production and early failure rate testing of complex logic and memory chips. Aehr's innovations chiefly serve the automotive, consumer electronics, and data storage markets, helping manufacturers enhance the quality and reliability of cutting-edge electronic products. |
Instruments for Measuring and Testing of Electricity and Electrical Signals | 764.54 | 1.12 |
| 385 |
|
BRY / Berry Corporation
Berry Corporation, based in the United States, primarily operates in the energy sector, focusing on the exploration and production of oil and natural gas. Predominantly active in California, it is one of the region's largest oil and gas producers, with significant projects centered on enhancing extraction and production efficiencies while adhering to stringent environmental and safety standards. Berry Corporation leverages advanced recovery techniques and strategic asset management to optimize its substantial resource base in conventional oil reservoirs, aiming to sustainably supply energy while maintaining a commitment to responsible environmental stewardship. The strategic focus is on maintaining cost-effectiveness and maximizing the value of its mature oil fields, ensuring steady performance in a fluctuating energy market. |
Crude Petroleum and Natural Gas | 248.31 | 1.12 |
| 386 |
|
HONE / HarborOne Bancorp, Inc.
HarborOne Bancorp, Inc., based in the United States, primarily operates in the banking industry, offering a broad spectrum of financial services. As a prominent entity in the Northeastern U.S., particularly Massachusetts, the company focuses on providing retail and commercial banking products. Essential services include checking and savings accounts, mortgage lending, auto loans, and business banking solutions. Additionally, through its subsidiary, HarborOne Mortgage, LLC, it significantly contributes to the residential lending market in its operational regions. A key project for HarborOne has been its strategic transformation from a credit union to a public bank in 2016, aimed at expanding its business capabilities and market reach. This shift underscores HarborOne's commitment to growth and innovation within the competitive financial services sector. |
State Commercial Banks | 517.43 | 1.12 |
| 387 |
|
INVZ / Innoviz Technologies Ltd. | Motor Vehicle Parts and Accessories | 319.23 | 1.12 |
| 388 |
|
ACCO / ACCO Brands Corporation
ACCO Brands Corporation, based in the United States, is a leading player in the office products industry globally. The company designs, manufactures, and markets a wide range of traditional and computer-related office products and supplies, including binders, staplers, shredders, and whiteboards under well-known brands such as Mead, Swingline, and Kensington. Operational since 1903, ACCO Brands has focused on expanding its product portfolio and market reach through strategic acquisitions, notably the purchase of General Binding Corporation in 2005 and MeadWestvaco's Consumer & Office Products division in 2012. These acquisitions have enabled ACCO to bolster its presence in key markets and enhance its product lineup, reinforcing its position as a dominant supplier to the office and school supplies sector. |
Blankbooks, Looseleaf Binders, And Bookbinding | 370.98 | 1.11 |
| 389 |
|
VANI / Vivani Medical, Inc. | Electromedical and Electrotherapeutic Apparatus | 77.61 | 1.11 |
| 390 |
|
PETS / PetMed Express, Inc.
PetMed Express, Inc., based in the United States, operates principally in the healthcare sector, specifically focusing on the pet pharmacy industry. Founded in 1996 and headquartered in Florida, the company has established itself as a leading online pet pharmacy, providing prescription and non-prescription pet medications, along with health and nutritional supplements. PetMed Express markets these products directly to the consumer through its website and via its toll-free number. A key project for the company has been enhancing its e-commerce platform to improve user experience and expand its product range. This strategy aims to address the growing demand for convenient and affordable pet care solutions, leveraging technology to streamline operations and engage effectively with a broad customer base. |
Drug Stores and Proprietary Stores | 1.11 | |
| 391 |
|
KMDA / Kamada Ltd. | Pharmaceutical Preparations | 405.11 | 1.11 |
| 392 |
|
NUVB / Nuvation Bio Inc. | Pharmaceutical Preparations | 1,329.58 | 1.11 |
| 393 |
|
TACT / TransAct Technologies Incorporated | Computer Peripheral Equipment, Not Elsewhere Classified | 45.53 | 1.11 |
| 394 |
|
SMHI / SEACOR Marine Holdings Inc.
SEACOR Marine Holdings Inc., based in the United States, operates in the global marine and support transportation services arena, primarily serving the offshore oil and gas exploration and production industry. As a significant player in its sector, SEACOR Marine specializes in providing a diverse range of marine assets for offshore oil and gas, government, and wind energy projects. The company’s fleet, among the most modern in the industry, includes support vessels that deliver cargo and personnel, towing rigs and servicing offshore installations, and handling anchors for drilling rigs and laying cables. With a focus on innovation and safety, SEACOR Marine continuously explores technological advancements to enhance its operational efficiency and environmental compliance, positioning itself as a leader in maritime services for various high-demand sectors. |
Deep Sea Foreign Transportation of Freight | 174.00 | 1.11 |
| 395 |
|
BITF / Bitfarms Ltd.
Bitfarms Ltd. is a publicly traded cryptocurrency mining company primarily involved in the production of Bitcoin. Based in Toronto, Canada, the company constitutes a significant presence in the blockchain sector by operating one of the largest cryptocurrency mining operations in North America. Bitfarms' key projects focus on expanding its mining capabilities and enhancing energy efficiency across its data centers that are strategically located to utilize cost-effective, predominantly hydroelectric power. This commitment not only to scale but also to sustainability, seeks to position Bitfarms favorably within an increasingly competitive and environmentally concerned market. The firm continually invests in the latest mining technology and infrastructure to ensure high operational efficiency and profitability in the volatile cryptocurrency landscape. |
Finance Services | 716.45 | 1.11 |
| 396 |
|
SENS / Senseonics Holdings, Inc.
Senseonics Holdings, Inc., based in the United States, operates within the healthcare sector, specifically focusing on the development and commercialization of glucose monitoring systems for people with diabetes. A prominent player in medical technology, the company's main product, the Eversense® Continuous Glucose Monitoring (CGM) system, distinguishes itself with its long-term implantable device. This system allows for continual glucose monitoring for up to 90 and 180 days, offering significant advantages in terms of convenience and efficiency compared to traditional CGM systems. The innovative nature of Senseonics' solutions aligns with their commitment to enhancing diabetic care management through advanced sensor technology and data integration capabilities. |
Industrial Instruments for Measurement, Display, and Control of Process Variables; and Related Products | 369.49 | 1.11 |
| 397 |
|
SKIN / The Beauty Health Company
The Beauty Health Company, based in the United States, operates within the health and beauty sector, primarily focusing on aesthetic skincare products and services. The company has gained prominence through its flagship brand, HydraFacial, a non-invasive skin treatment that combines cleansing, exfoliation, extraction, hydration, and antioxidant protection. This proprietary technology serves both the professional and consumer markets, emphasizing customizable skincare solutions. The Beauty Health Company actively pursues innovation in dermatological health, continuously expanding its product offerings to include various skin-enhancing treatments and serums that cater to diverse customer needs globally. The company's strategic initiatives aim to further penetrate the medical aesthetics market, highlighting a commitment to delivering clinically effective solutions that foster consumer confidence and loyalty. |
Surgical and Medical Instruments and Apparatus | 259.87 | 1.11 |
| 398 |
|
ACHV / Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc., based in the United States, operates within the biopharmaceutical industry focused on developing and commercializing novel treatments for addiction and related disorders. One of its key projects involves the development of cytisinicline, a plant-based alkaloid with a high-binding affinity to the nicotinic acetylcholine receptor, aimed at aiding smoking cessation. This compound represents a significant breakthrough in addressing nicotine addiction, offering a potential alternative to traditional therapies with a differing mechanism of action. Life Sciences is advancing its clinical development, actively engaging in multiple phase 3 trials to further evaluate the efficacy and safety of cytisinicline for broad therapeutic use. |
In Vitro and In Vivo Diagnostic Substances | 140.61 | 1.10 |
| 399 |
|
NKTX / Nkarta, Inc. | Pharmaceutical Preparations | 160.52 | 1.10 |
| 400 |
|
DYN / Dyne Therapeutics, Inc. | Electric Services | 1,625.90 | 1.10 |
| 401 |
|
SHOT / Safety Shot, Inc. | Perfumes, Cosmetics, and Other Toilet Preparations | 39.01 | 1.10 |
| 402 |
|
INVE / Identiv, Inc.
Identiv, Inc. is a technology company based in the United States that operates primarily within the security and identity management sector. Established in 1990, Identiv's focus is on developing and providing scalable security solutions for enterprises, government entities, and consumers. Its core products include physical access control systems, identity management services, and RFID-enabled applications. The company has increasingly levered its expertise into critical areas such as federal government security and IoT-based solutions, consistently aiming to address modern cybersecurity and identification challenges. Key projects have expanded into areas such as secure authentication and embedded credentialing technologies, which have relevance in corporate settings, healthcare, education, and potentially even consumer products. Identiv’s strategic endeavors reflect its commitment to innovation and security in the digital age, keeping it at the forefront of its industry. |
Computer Peripheral Equipment, Not Elsewhere Classified | 91.59 | 1.09 |
| 403 |
|
VWAV / VisionWave Holdings, Inc. | 25.89 | 1.09 | |
| 404 |
|
FNKO / Funko, Inc.
Funko, Inc., based in the United States, is a prominent player in the collectibles industry, specializing in the design, sourcing, and distribution of licensed pop culture products. Established in 1998, Funko is renowned for its broad array of licensed vinyl figurines and bobbleheads, which it markets under the popular Pop! brand. The company collaborates with numerous major entertainment companies, covering a wide range of content from movies, TV shows, and video games to sports and music. The diversification and appeal of its product lines have positioned Funko as a cultural and commercial leader in the novelty and collectibles market sector. Further strengthening its market position, Funko has expanded into apparel, accessories, and digital experiences, including the development of immersive virtual products and interactive gaming initiatives, which enhance its traditional revenue streams and engagement with a global consumer base. |
Games, Toys, and Children's Vehicles, Except Dolls and Bicycles | 178.31 | 1.09 |
| 405 |
|
INBX / Inhibrx Biosciences, Inc. | Biological Products, Except Diagnostic Substances (Biotech) | 407.93 | 1.09 |
| 406 |
|
RNA / Avidity Biosciences, Inc. | Pharmaceutical Preparations | 6,082.98 | 1.09 |
